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1.1 Role of Protein Phosphatases  in biological systems 
The reversible phosphorylation of proteins catalyzed by protein kinases and protein 
phosphatases (Fig.1) determines the biological activities of many proteins and it is 
recognized as a major mechanism controlling cellular processes in both prokaryotes and 
eukaryotes1,2. 
 
           Fig.1: Reversible phosphorylation of proteins.  
 
In eukaryotes, during protein phosphorylation, phosphate moieties are transferred to the 
serine, threonine or tyrosine residues of proteins from adenosine triphosphate molecules by 
protein kinases, and are hydrolysed by protein phosphatases2. In addition, phosphorylation 
occurs on the basic amino acid residues histidine or arginine or lysine in prokaryotic 
proteins 3. 
Many dephosphorylation processes can result in changes in polypeptide folding, enzymatic 
activity and protein–protein interactions and they are proved to occur very frequently in 
both intra- and extracellular processes. Phopshatases are involved in:  
- signal transduction cascades and the general effect of dephosphorylation, in many cases, 
is to provide an 'on-off switch' for signalling pathways 4-6; 
- signalling  in the nucleus. The importance of phosphorylation in this  highly dynamic 
cellular compartment is related to its dominant regulatory role in processes as diverse as 
DNA replication and repair, chromosome condensation, ribosome biogenesis and 
chromatin remodelling7-9; 
- exocytosis 10,11; 
- cell-matrix adhesion and migration 12. 
 
Kinases 
Phosphatases 
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Many other specific biological roles of phosphatases are reported in Tab.1 where the most 
recent classification of these enzyme is shown 8. 
1.2  Protein Phosphatases Gene  Families: a focus on Human Protein 
Serine/Threonine Phopshatase PP5 , PP2A and PP6 
According to the last evolutionary studies,  human protein phosphatases can be classified 
into three groups on the basis of sequence, structure and catalytic mechanism13. A recent 
classification of human phosphatases is reported in Tab.1. 
 
Tab.1: Main features and classification of  Human Protein Phosphatases  (Reprinted from Kerk et al.13) 
Family Class Regulatory Subunits Example of function 
and/or (substrate) 
Ser/Thr phosphatases 
PPP family PP1 Yes Chromosome condensation 
 PP2A Yes Chromatid cohesion 
 PP4 Yes DNA repair 
 PP5 None Cellular stress 
 PP6 Yes NFkB pathway 
 PP2B Yes Immune response  
 PP7 Unknown  
PPM family PPC None TGFß signalling 
PTP superfamily 
Class I PTPs Receptor PTP  Cell adhesion/cytoskeletal 
 Non-receptor PTP  Insulin signalling (insulin 
receptor) 
Class I PTPs (DSPs) MAPKP  MAPK (MAPK) 
 Slingshots  Actin dynamics (cofilin) 
 PRLs  Unknown 
 Atypical DSP  Mostly unknown (mRNA) 
 CDC14  Cytokinesis, mitotic exit 
 PTEN  PIP phosphatase 
 Myotubularins  Ptdlns3P, Ptdlns(3,5)p 
phosphatase 
Class II PTPs CDC25s  Promotes mitosis 
Class III PTPs LMWPTP  Unknown 
Asp-based catalysis  
FCP/SCP family FCP1 Yes Transcription (pol II) 
 SCP  TGFß signalling (SMADs) 
 FCP/SCP-like  Unknown 
HAD family   Actin dynamics (cofilin) 
  
The first group comprises the classic Ser/Thr phosphatases: the large phosphoprotein 
phosphatase (PPP) family (PP1, PP2A, PP2B, PP4, PP5, PP6 and PP7) and the protein 
phosphatase, Mg2+ or Mn2+ dependent (PPM) family (PP2C). They catalyze the 
dephosphorylation of serine and threonine residues. The protein Tyr phosphatase (PTP) 
superfamily forms the second group and they dephosphorylate the tyrosine residues of their 
substrates. The third group consists of the Asp-based protein phosphatases with a 
DXDXT/V catalytic signature. In general, genomics studies showed that there are 147 
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human protein phosphatases. In human phosphoproteome, proteins are phosphorylated 
predominantly on Ser, Thr and Tyr residues, with each accounting for approximately 86.4, 
11.8 and 1.8%, respectively 7. 
Although over 98% of protein-phosphorylation occurs on Ser and Thr side chains, only 
40 of the 147 known protein phosphatases are specific for these residues 8. The fact that 
also the total number of phosphatases is significantly lower than the number of kinases 
implies that some phosphatases have more than one function12. Dephosphorylation brought 
about by protein Ser/Thr phosphatases  represents a relevant cellular process  and  
investigations aimed at understanding phosphatase catalysis are needed.   
In mammals, PPP family consists of multiple high homologies isoforms with peculiar 
specificities. In particular, there are three isoforms of PP1 (identity >90% ), two isoforms 
of PP2A (identity >97%),  and three isoforms of PP2B (identity >80%). All but one, PP7, 
are ubiquitously expressed in the organism 14. 
PP2A, PP5, and PP6 are largely expressed in humans but their specific biological functions 
are still poorly characterized although different studies show their involvement in cell cycle 
regulation, apoptosis and stress response 15-18. 
The members of the PPP family show common structural features and distinctive 
characteristics. In particular,  all PPP proteins share a catalytic domain containing two 
metal ions. At the same time, regulatory subunits that restrict and control the catalytic 
activity and regulate the substrate specificity have been identified in PP1, PP2A, PP4, 
PP2B and  PP619 ,20, 21-23.  A short N-terminal section TPR domain with autoinhibitory 
function distinguish PP5 from the other members. Moreover, a C-terminal region that 
includes an unusual nuclear localization sequence posses an  autoinhibitory function, too24. 
The catalytic domain of PP5 (PP5c) shares 35-45% sequence identity with the catalytic 
domain of other PPP phosphatases25. 
For all serine/threonine phosphatase, a common catalytic mechanism of metal ion-mediated 
hydrolysis has been proposed27. 
1.3 Catalytic mechanism 
As all the phosphatases belonging to PPP family, PP5 is a metalloprotein in which highly 
conserved three motifs (GDXHG, GDXXDGR and GNH(E/D) in the N-terminal 
subdomain of catalytic domain are present26. These motifs contain most residues which 
coordinate metal ions in the active centre and are considered as the signature of the 
phosphatase family27. 
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X-ray crystal structure of other related phosphatases (Protein phosphatase 1 and Protein 
phosphatase 2B) revealed in their catalytic subunit a metal-bound water molecule acting as 
a nucleophile to attack the phosphorus atom of a phosphate group in a SN2 mechanism. 
Metals assist in this catalysis as Lewis acids. Protein phosphatase 2C  too contains 
binuclear metal ions (2 Mn2+) in its catalytic site. It promotes protein dephosphorylation by 
activation of water molecules to catalyse hydrolysis in a single-step reaction 27,28. The 
catalytic mechanism of  PP5 has been proposed by Swingle et al. (Fig.3)25 . Precise 
positioning of two metal ions within a conserved Asp271-Metal1:Metal2-Water-His427-
His274-Asp274 catalytic motif is requested 25,27. 
 
Fig.3: Catalytic activity metal ion-mediated hydrolysis of PO3 derived from the crystal structure of 
PP5c. The attacking hydroxide W1 is shown in blue, and the leaving group of the substrate is in green. The 
substrate, the planar PO3 moiety of the transition state, and the phosphate product are all shown in red. Solid 
lines to the metal ions denote metal-ligand bonds, and solid or dashed wedges indicate metal-ligand bonds 
directed above or below the plane of the page, respectively. Wavy lines to the metal ions indicate strained 
contacts with poor coordination geometry. Dotted lines indicate hydrogen bonds, and the nearly dissociated 
axial bonds in the transition state are shown by half-dotted double line (Reprinted from Swingle et al.25). 
 
Despite these similarities in sequence, each phosphatase in the PPP family appears to have 
different metal ion requirements29. The dinuclear metal site is situated in a unique protein 
fold, a β-α-β-α-β motif which provides the majority of ligands to the metal ions. A similar 
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fold is also seen in plant purple acid phosphatases where the two metal ions are bridged by 
a solvent molecule and a carboxylate group from an aspartic acid residue, juxtaposing the 
two metal ions to within 3.0–4.0Å of each other. A similar motif has been identified in a 
number of other enzymes which exhibit phosphoesterase activity, implicating that several 
of them are metalloenzymes which contain dinuclear metal ion cofactors30. However, the in 
vivo identities of relevant metal ions in most PPP family phosphatases have not been 
completely resolved except for PP2B, PP1 and PP2A for which a dinuclear center 
containing respectively Fe2+ /Zn 2+,  Mn 2+/Fe 2+ and Mn2+/Mn2+ was identified31-33 . A 
bimetallic center cotaining Mn2+/Mn2+ has been identified also  in the bacteriophage λ 
protein phosphatase (PP λ)31. 
Manganese is required in the formation of an active metalloenzyme form of PP1 but its 
treatment with a combination of iron and zinc lead to a more active PP134. Because the 
catalytic domains of PPP members are so highly conserved, PP2B and PP1 has been  
recently used as a model system for studying the PPP family 35 as well as the PP λ that was 
found to represent the minimal catalytic core of PP5 and PP136. In this PhD project further 
structural and biochemical investigations have been focused on the catalytic domain of 
PP5. 
1.4 PPPs as pharmaceutical targets 
The catalytic activity of protein phosphatases is crucial for cellular life. Dysregulated 
phosphorylation/dephosphorylation in humans underlies numerous diseases 10,37. 
Embryogenesis, angiogenesis, nerve growth, tissue repair, inflammation, atherosclerosis, 
arthritis, osteoporosis, invasion and metastasis are all biological processes that require cell 
attachment and migration in which many phosphatases are involved. Abnormal 
phosphorylation has been associated with excitotoxicity, in response to perturbed calcium 
homeostasis. Neuronal loss due to excitotoxicity may contribute to the pathophysiology of 
chronic neurodegenerative illnesses such as Alzheimer’s disease, amyotrophic lateral 
sclerosis, Parkinson’s disease 10.  
Therefore, the targeting of phosphatase activity might represent a new approach to treat 
specific diseases and to study PPP function. In the case of holoenzyme, the association with 
multiple regulatory subunits is considered the basis for achieving diversity of biological 
functions and modulation of enzymatic activity. Therefore, both the catalytic domain and 
the regulatory subunits represent a possible pharmacological targets.  
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During this PhD project, among the members of PPP family, PP2A, PP6 and PP5 have 
been cloned and expressed. While for PP5 soluble constructs of the catalytic domain with 
and without the autoinhibitory domain have been successfully expressed, purified and 
characterized, for PP2A and PP6 the research activity is still in progress, due to the 
difficulties in obtaining soluble forms of the enzyme in E.coli and in cell-free system. 
 
PP5 
Protein phosphatise 5 has been investigated and structurally characterized by Yang and 
Swingle 25,28 that have revealed important aspects of the catalytic mechanism and enzyme 
regulation. PP5 is constituted by an N- terminal TPR domain, by a catalytic domain and by 
a C-terminal subdomain. TPR domain acts as an interface for protein-protein interactions in 
several proteins included PP5 38,40. The best-known binding partners of PP5 is the Heat 
Shock Protein 90 (HSP90) that binds PP5 throught the EEVD sequence41,42. 
In PP5, the TPR-domain has an additional function, e.g. to keep the enzyme inactive in 
concert with the C-terminal domain. Actually, the interaction of TPR with the catalytic 
domain restricts the access to the catalytic site. Due to this, PP5, unlike other phosphatases, 
displays low-phosphatase activity under normal conditions, but it can be activated when the 
TPR domain is displaced or truncated from PP5 43. A model for the in vivo activation and 
regulation of PP5 has been proposed by Zeke in 2006 44 and is shown in Fig. 2. 
PP5 protein can be activated by glucocorticoid receptor–Hsp90 complexes, by other Hsp90 
complexes or by the interaction of TPR domain with other ligands and proteins41,43,45,46. It 
is expressed in all mammalian tissues, with high levels in brain and neurons. Within the 
cell,  this enzyme is also broadly distributed. PP5 is involved in several phosphorylation 
cascades including MAPK-mediated growth and differentiation, cell cycle arrest and DNA 
damage repair via the p53 and ATM/ATR pathways, regulation of ion channels via the 
membrane receptor for atrial natriuretic peptide, the cellular heat shock response as 
mediated by heat shock transcription factor, and steroid receptor signaling, especially 
glucocorticoid receptor (GR) 47. 
It has been recently suggested a potentially important regulator role of PP5 in human breast 
cancer 48-50 and in neurodegenerative disease like Alzheimer’s disease, where the 
dephosphorylation /hyperphosphorylation of Tau protein play a crucial role in intracellular 
neurofibrillary tangles51,52. Therefore, PP5 is a promising therapeutic target in the treatment 
of these diseases. In order to interfere with the biological activity of the enzyme, both the 
catalytic site and the regulation mechanism can be targeted by designing specific 
molecules. 
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Fig.2: PP5 in vivo regulation: a model. Proteolytic cleavage may remove the C-terminal hatched region or 
the N-terminal grey section. Newly synthesized PP5 forms a complex with Hsp70. Via multichaperone 
complexes, Hsp90 may displace Hsp70, and PP5 bound to Hsp90 may move to the nucleus in a low-activity 
form. In response to stress stimuli, PP5 (58 kDa) dissociates from the Hsps and is proteolytically cleaved at 
either the C-terminus (50kDa isoform) or the N-terminus (56kDa isoform). Cleavage at the C-terminus allows 
PP5 to translocate to the cytoplasm. A small fraction of proteolytically cleaved PP5 may form dimers (or 
multimers) by interaction of the TPR domains, which may serve as a store for the production of active 
monomers. Proteolytic cleaved PP5 monomers dephosphorylate phosphoprotein substrate. The phosphate 
moiety of the substrate may initially bind to the TPR domain, allowing the phosphatase domain to catalyse 
the cleavage of phosphate from the substrate. Active PP5 is then polyubiquitinated and destroyed via the 
proteasome 44. 
 
 
PP5 activation  
Activation of protein phosphatase 5 can occurs by limited proteolysis or the binding of 
ligands to the TPR domain that seems to acts by inducing a conformational change in the 
enzyme making the catalytic site accessible to substrates. Two potential physiological 
activators (long chain fatty acid-CoA esters and the C-terminal domain of the heat shock 
protein 90) have been identified 53 looking at which some new molecules can be designed 
to modulate PP5 activity. 
 
PP5 inhibition 
In general, the physiological importance of protein phosphatase 5 is demonstrate by the fact 
that it is the target of many naturally occurring toxins 54. 
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PP5 is reported to be sensitive to inhibition by okadaic acid, microcystin, cantharidin, 
tautomycin and calyculin A 55. 
Structural analysis of human PP5 showed that the mechanism of TPR inhibition of the 
phosphatase domain is similar to the mechanism of inhibition of PP2B by its C-terminal 
regulatory segment and to that of PP1 by toxins 28. 
Apparently, inhibitor molecules show their inhibitory function by interacting with the 
catalytic site of the enzyme. 
Phosphatase inhibition has become one of the major area for therapeutic intervention 56-58 
and drug design in pharmaceutical companies becomes increasingly important in an ageing 
society. Anyway, efforts in the field of structure-based design of protein phosphatase 
activators/inhibitors and ligand screening methodology are  strongly appreciated. 
1.5 Aims and topics of the research 
The present PhD project was focused on the development of new tools that can support a 
structure-based drug discovery research on metallophosphatases and on a detailed 
characterization of protein phosphatase 5 that is  a representative member of PPP family.  
Attention was mainly devoted on the structural and functional characterization of the 
catalytic domain of serine/threonine phosphatase PP5. This protein is known to participate 
in signaling networks that either initiate or regulate a variety of cellular events.  
Another goal of the research was to clarify the biological role of different metal ions in the 
regulation of PP5 activity. 
There have been several studies that directly implicate PP5 in the development of many 
diseases like cancer and Alzheimer’s syndrome. To better define the biological roles of PP5 
and to develop novel antitumor drugs, specific inhibitors of PP5 are desired. PP5 is 
sensitive to inhibition by several natural toxins commonly employed to study the actions of 
PP1 and PP2A.  In this respect  the interaction of PP5 with a group of structurally related 
inhibitors (cantharidin, cantharidic acid and endothal) has been investigated by X-ray. The 
three-dimensional structures obtained during the present research have been compared with 
the few adducts of protein phosphatases already available in the protein databank. The 
informations obtained have provided new hints to elucidate the structural determinants 
relevant for the inhibition of protein phosphatases. During the present research a new 
ligand screening approach based on the analisys of the relaxation rate of water proton has 
been developed. Relaxometry, that is not so popular as high resolution NMR, is able to 
provide structural and dynamical informations on diamagnetic and paramagnetic proteins. 
The relaxometric approach, here decribed, provides informations  on  the affinity constant 
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and on the binding mode of the ligand by using very low ammount of protein and 
inhexpensive instrumentation. Moreover, relaxometric approach can be used in a high-
throughput screening strategies for  large libraries of compounds or already identified 
ligands. 
 
A part of the work has been focused on the expression of other members of PPP family 
using an alternative protein expression technique. Starting from the observation that the 
human recombinant proteins are usually difficult to be expressed in E. coli  system, the  in 
vitro cell-free system has been taken into consideration even if further optimization in the 
protocol steps are still in progress. 
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2.1 Structural and Functional Genomic 
Impressive progress in genome sequencing, protein expression and high-throughput 
crystallography and NMR has radically transformed the opportunities to use protein three-
dimensional structures to accelerate drug discovery, but the quantity and complexity of the 
data have ensured a central place for informatics. Structural biology and bioinformatics 
have assisted in lead optimization and target identification where they have well 
established roles; they can now contribute to lead discovery, exploiting high-throughput 
methods of structure determination that provide powerful approaches to screening of 
fragment binding1. With the advent of modern high throughput technologies in both 
genomics and biological screening, and at the same time the enormous advances in 
computer technology, it is now feasible to use these tools in rational approaches in the 
search for new medicines. 
The genome sequencing projects developed in the last few years have made available the 
primary sequence of an enormous number of new genes. The draft sequence of the human 
genome 2,3 is now available together with the complete genomes of many other organisms 
(Web site: www.ncbi.nlm.nih.gov). This wealth of genomic data can be fully exploited 
only through elucidation of the three-dimensional structures of the corresponding proteins. 
The availability of the human genome provides access to a broad variety of phosphatases. 
Thus, the use of  sophisticated techniques to identify potential inhibitors allows systematic 
structure-based drug design, that is the final objective of the “classic” Structural Genomics. 
 
The study of the protein function can be achieved by the identification, production and 
characterization of partner proteins and by protein-protein interaction studies. The various 
Structural Genomics initiatives commencing worldwide differ in the choice of protein 
targets in an effort to provide a complete coverage of protein structures and relative 
associated function. So, there are actually two different possible philosophies that 
distinguish the various research consortia.  
The Structural Genomics projects are characterised by a High-Throughput Production 
(HTP) of proteins and structures, and the goal of this kind of projects is to provide a 
complete repertoire of protein folding by determining a representative structure. In this case 
the effort for the target selection is limited. Entire genomes or very large protein families 
(e.g.: all soluble human proteins under 100 residues) are selected, cloned and expressed in 
parallel using automatic systems. The great advantage of this approach is that a huge 
number of genes are screened for protein expression and solubility. However, a common 
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cloning and expression protocol has to be used for all the genes, limiting the rate of success 
(usually 20-30%) for each target.  
The Functional Genomics projects use a Medium Throughput Production approach (MTP) 
and focus the effort on a limited number of proteins that are linked to diseases or are 
involved in some specific metabolic pathways. Large bibliographic and bioinformatics 
research is at the basis of the target selection. A limited number of targets are cloned but, in 
order to maximize the rate of success, many simultaneous cloning and expression strategies 
are performed. 
For both strategies a multidisciplinary approach is necessary; different scientific fields like 
bioinformatics, biochemistry and molecular biology have to cooperate in order to proceed 
in the target selection, protein expression, and finally structural and functional 
characterization.  
In this work, the multidisciplinary approach was applied to study Protein Phosphatases. In 
particular, NMR spectrospcopy, X-ray and relaxometry have been used to get informations 
on physiological metals of the targeted metalloenzyme, on its catalytic mechanism and on 
inhibition operated my small molecules. 
2.2 Genome browsing and domain definition 
One of the main challenges facing the molecular biology community today is to make 
sense of the wealth of data that has been produced by the genome sequencing projects. In 
the past decade, bioinformatics has become an integral part of research and development in 
the biomedical sciences. Bioinformatics now has an essential role both in deciphering 
genomic, transcriptomic and proteomic data, generated by high-throughput experimental 
technologies, and in organizing information gathered from traditional biology. It is an 
interdisciplinary research area at the interface between the biological and computational 
science. The ultimate goal of bioinformatics is to uncover the biological information hidden 
in the mass of data and obtain a clearer insight into the fundamental biology of organisms.  
A number of data banks with databases and programs have been created with the aim of 
providing the scientific community with tools for searching gene banks, for the analysis of 
protein sequences, for the prediction of a variety of protein properties. Primary databases 
contain information and annotations of DNA and protein sequences, DNA and protein 
structures and protein expression profiles. 
Some available databases for genome browsing are: 
• NCBI (www.ncbi.nlm.nih.gov/Entrez/) - This web site integrates information from 
several databases (Swissprot, EMBL, all geneBank, etc...) 
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• PDB (www.rcsb.org/pdb) - A 3-D biological macromolecular structure database 
• Pfam (http://pfam.wustl.edu) - A collection of different protein families organized 
in terms of different domains as obtained from multiple alignment. 
Secondary or derived databases are so called because they contain the results of 
analysis of the primary resource including information on sequence patterns or motifs, 
variants and mutations and evolutionary relationships.  
Once all biological data is stored, the requirement is to provide bioinformatics tools for 
extracting the meaningful information. 
The most used programs for genome browsing are: 
• BLAST (www.ncbi.nlm.nih.gov/BLAST/): Standard BLAST (Basic Local 
Alignment Search Tool) is a set of similarity search programs designed to explore 
all of the available sequence databases regardless of whether the query is protein or 
DNA. PHIBLAST is designed to search for proteins that contain a pattern specified 
by the user, and simultaneously are similar to the query sequence. 
• CLUSTALW (www.ebi.ac.uk/clustalw/) is a general purpose multiple sequence 
alignment program for DNA or proteins. It produces biologically meaningful 
multiple sequence alignments of divergent sequences. It calculates the best match 
for the selected sequences, and lines them up so that the identities, similarities and 
differences can be seen. Evolutionary relationships can be seen via viewing 
Cladograms or Phylograms 
• PROSITE (www.expasy.org/prosite/) SCANPROSITE allows to scan a protein 
sequence, provided by the user, for the occurrence of patterns and profiles stored in 
the PROSITE database, or to search in protein databases all sequences with a user 
entered pattern. 
• STRING (dag.embl-heidelberg.de) STRING is a database of predicted functional 
associations among genes/proteins. Genes of similar function tend to be maintained 
in close neighbourhood and tend to be present or absent together. 
Once individuated a protein of particular interest, this is subjected to further bioinformatics 
investigations in order to predict important features like stability, solubility, 
hydrophobicity, secondary and tertiary structures. 
For each target protein several domains are selected for expression, and of these domains 
various construct are cloned in order to increase the probability of obtaining a soluble and 
well-folded protein. Domain selection and construct design are performed considering 
several aspects. 
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The first important step is to perform the transmembrane regions prediction using dedicated 
bioinformatics programs. (e.g. TMHMM: www.cbs.dtu.dk/services/TMHMM-2.0) The 
result of this analysis make us know if we are dealing with a completely soluble protein, 
with an integral transmembrane protein or with a protein mainly soluble with a small 
portion inserted into the phospholipidic bilayer. In the latter case it is possible to try to 
express a recombinant protein without the transmembrane tail. Using the program 
SIGNALP (www.cbs.dtu.dk/services/SignalP) it is also possible to predict the presence of a 
signal-peptide sequence that enables the expression of the protein in the periplasmic area. 
Another important analysis is the secondary structure prediction, exploiting the web server 
http://npsa-pbil.ibcp.fr/, in order to have an indication of the regions with tendency to form 
helices, beta-sheet, coil or turns. Combining these predictions with ClustalW alignments of 
the protein family, we can evaluate which is the best residue where to cut the domain, still 
maintaining the correct folding of the protein. It is also useful to search for the presence of 
intrinsically unstructured/disordered region using IUPred (http://iupred.enzim.hu/).  
Once individuated a protein of particular interest, this is subjected to further bioinformatics 
investigations in order to predict important features like stability, solubility, 
hydrophobicity, secondary and tertiary structures. 
On the basis of bioinformatic analysis and solubility predictions the following Protein 
Serine/Threonine Phosphatases were taken into consideration and the following constructs 
have been selected: 
PP2A catalytic domain: PP2Ac (residues 1-290) and PP2Ac1 (residues 23-290) 
PP6 catalytic domain: PP6c (residues 1-298) and PP6c1 (residues 1-305) 
PP5: 16-499 
PP5 catalytic domain: PP5c (residues 169-499)  
2.3 DNA preparation techniques 
2.3.1 Gene cloning 
 
In the Functional genomic approach, the cloning strategy has to be carefully designed, 
since it will influence the behaviour of the target protein, e.g. yield, solubility, folding, etc. 
The best strategy to maximize the probability of obtaining a soluble and correctly folded 
target protein is to select, following preliminary bioinformatics analyses, several different 
domains and clone each domain into several different expression vectors, which allow the 
expression of the target not only in the native state, but also using several different fusion 
partners. They are reported to assist protein solubility and folding 4. 
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Even if the number of fusion partners is increasing progressively during the years it has 
been experienced that none of these tags work universally with each partner protein. 
 
Classical cloning  uses restriction enzymes that cut the DNA of interes at specific 
recognition sites. To be able to clone a DNA insert into a cloning or expression vector, both 
have to be treated with two restriction enzymes that create compatible ends. The next step 
is the ligation of the insert into the linearized vector. This involves the formation of 
phosphodiester bonds between adjacent 5'-phosphate and 3'-hydroxyl residues, a reaction 
catalyzed by the bacteriophage T4 DNA ligase. Finally an aliquot of this reaction is 
transformed in DH5α E. coli competent cells and positives clones are screened both by 
PCR and DNA sequencing. The yield of all this procedure is particularly influenced by the 
ligation step that is dependent from several factors, like DNA concentration, vector/insert 
ratio and transformation efficiency of the cells. Moreover the parallelization of this 
approach is not so easy because it is a very time-consuming technique and not all the host 
vectors and the target genes can be cut with the same restriction enzymes. 
 
When recombinant proteins are expressed in vivo, genes are typically subcloned and 
expressed from medium- or low-copy plasmids to avoid residual gene expression or 
“leakiness” that occurs in high-copy plasmids. Low-copy plasmids provide a lower gene 
dosage, which minimizes background levels and maintains tight regulation of expression 5. 
In a in vitro protein synthesis (also called cell-free, see paragraph 2.4.2) high copy plasmids 
are used beacuse high quantity of available DNA template is required.  
A more recent cloning technique, called Gateway technology, was described by Landy et 
al. 6 (Fig. 5). This technique  allows a rapid cloning of one or more genes into virtually any 
expression vector using site-specific and conservative recombination (LR reaction), thus 
eliminating the requirement to work with restriction enzymes and ligase. Moreover,  the 
Gateway system resulted faster due to the higher reaction efficiency and less sequencing 
demand since only the starting pENTR should be sequence verified. 
 
PP5c, PP2Ac/c1 and PP6c/c1 constructs were cloned according to the  Gateway technology. 
Different fusion tags have been used (His, GST, MBP, NusA, Trx, GB1). PP6 c/c1 and 
PP2A c/c1 have been also cloned inside an expression vector that does not contain any 
fusion tag in order to get native proteins.  
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High copy expression vectors are usually used in cell-free system. The MCSI vector, a pET 
derivative plasmid, has been used in this work and cloning has been performed according 
to the classical ligase reaction. 
Vector deriving from Gateway cloning have been used to test the expression of PP6  c/c1 
and PP2A c/c1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5:Gateway® technology principle. The startegy facilitates cloning of genes, into and back out of, 
multiple vectors via site-specific recombination. Once a gene is cloned into an Entry clone, the DNA 
fragment can be moved into one or more destination vectors simultaneously (Reprinted from Invitrogen 
website) 
 
2.3.2 PCR amplification for in vitro expression 
Large-scale plasmid preparation in in vitro expression system  is not always required 7.  
In the last years, a new technique has been developed. Starting from a DNA as template, 
some PCRs steps are carried out, generating stable PCR templates ready to be used in in 
vitro  transcription/translation system.  This startegy it is more expensive  but faster than 
the classic cloning technique and it also offers the advantage to have more pure DNA 
preparations. The  obtained template contains all the elements that are needed to start the 
transcription of the target gene  (Fig.6).  
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This technique still remain to be experienced in our laboratories since we have been carring 
out the in vitro synthesis  by using expression vectors deriving from Gateway cloning.  
 
 
 
Fig.6 Generation of stable PCR templates from a construct with aT7 f10 promoter, a ribosome binding 
site, and a T7 terminator (Reprinted from Wu et al.7). 
 
2.3.3 Site-directed mutagenesis 
The functional analysis of a protein often requires the generation of a number of single 
or multiple amino acid variants of the wild type gene. Site-directed mutagenesis is a 
technique for carrying out vector modification and characterizing the dynamic, complex 
relationships between protein structure and function. The basic procedure utilizes a 
supercoiled double-stranded DNA vector with insert the gene of interest and two synthetic 
oligonucleotide primers, both containing the desired mutation. The primers, each 
complementary to opposite strands of the vector, are extended during PCR reaction by a 
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high fidelity DNA polymerase (PfuUltra, Stratagene). Extension of the oligonucleotide 
primers generates a mutated plasmid. After PCR reaction, the product is treated with an 
endonuclease specific for methylated and hemimethylated DNA, DpnI. This enzyme is 
used to digest the parental DNA template and thus select only the mutation-containing 
synthesized DNA; this happens because DNA isolated from almost all E. coli strains is dam 
methylated and therefore susceptible to endonuclease digestion. The vector containing the 
desired mutations is then transformed into XL1-Blue supercompetent cells and 
subsequently subjected to sequencing analysis. 
Insertion of a PCR fragment into a recipient plasmid DNA can be performed expanding the 
Site-directed mutagenesis technique without using restriction enzimes. This methods was 
recently optimized by Novartis 8. 
Originally, the expression vector containing PP5 full-lenght gene  was generate to express a 
GST- PP5- His-tagged protein. While it was possible to remove the GST, the absence of a 
tag-removal enzyme site in the protein sequence made not possible the His-tag removal. 
The presence of an His-tag has been supposed to influence the  binding of metals in the 
catalytic pocket. The Novartis mutagenesis strategy was used to engineerize a new 
expression vector containing a TEV recognition site at the PP5 C-terminus. 
2.4 Protein expression 
2.4.1 In vivo expression 
E.coli expression system is, nowadays, the most widely used, since it is the easiest, 
quickest and cheapest one. Soluble  protein expression has continued to be a major 
bottleneck in the field though by the moment that many proteins belonging to interesting 
families, especially the human proteins, are often accumulated as inclusion bodies. E. coli 
is a prokaryote and lacks intracellular organelles, such as the endoplasmic reticulum and 
the Golgi apparatus that are present in eukaryotes, which are responsible for post-
translation modifications of the proteins being produced. Many eukaryotic proteins can be 
produced in E. coli, but sometimes they are produced like a non-functional inclusion bodies 
protein, since glycosylation or post-translational modifications such as proteolytic 
processing, folding and disulfide bond formation do not occur.  
Because of this, considerable efforts are still in progress in order to optimize both the in 
vitro refolded processes  and alternative strategies (mammalian, yeast and insect host) for 
overcoming some of the problems inherent in soluble and membrane protein expression9. 
As general  strategy, a  preliminary expression test is performed in a small-volume scale 
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using different strains (e.g.:, Bl21 (DE3) Gold, Bl21 (DE3) pLysS a protease deficient 
strain, Rosetta (DE3) and Bl21 (DE3) RIPL for genes containing rare codons and Origami 
(DE3) for proteins containing disulphide bounds), three expression temperatures (37-25-
17°C), three inducer (arabinose or isopropyl-beta-D-thiogalactopyranoside) concentrations, 
different induction times (4h and 16h) and three culture media of different composition. 
Expression results has been checked on SDS polyacrilamide gel (SDS-PAGE). This kind of 
approach allows us to explore a large set of expression conditions and to evaluate which 
one gives the best yield of soluble protein.  
Factors such as reduced temperature, changes in the E.coli expression strain or induction 
conditions and co-expression of molecular chaperones have all been deeply examined at 
this step and refinement of the expression conditions for the soluble proteins made before 
starting massive culture that is performed in flasks or fermentors to increase protein yield 
and have a better parameter control (e.g. pH, temperature and  pO2).  
If all the proteins are expressed in the insoluble fraction as inclusion bodies, the choice falls 
in redefining the domain, in proroceeding with an “ in vitro” refolding screening or in 
turning into a different expression system. 
2.4.2 In vitro expression 
Cell-free protein synthesis is an alternative strategy for overcoming some of the problems 
linked to the in vivo expression system . Many reviews can be found in literature 10-14. The 
principle of the in vitro protein synthesis is based on the production of proteins without the 
use of  living cells. The necessary catalytic machinery required for metabolism, 
transcription, translation, and proper folding in vitro is extracted from a living source. To 
date, a number of lysates have been successfully prepared, including E. coli, yeast, rabbit 
reticulocyte, wheatgerm, a hyperthermophile, Drosophila embryo, hybridoma, Xenopus 
oocyte or egg, insect, mammalian and human cells. 
The cellular extract preparation represent one of the critical step in cell-free technology. 
Soft cell-lysis must be performed by the moment that sonication may completely or 
partially destroy ribosome apparatus, thus resulting in a not-working translation. 
The most used source is E.coli because it is easy to menaged with . This cellular extract is 
named S30 because it is obtained by centrifuging the lysated cell at 30 000g, that is the 
right speed to get a functional catalytic machinery. 
The system lacks of a cell wall or membrane barrier, and of requirements to satisfy 
biochemical needs associated with growth and maintenance of a living cell. This aspect is 
hightly advantegeous because energy and other resources can be more focused and 
efficiently utilized for processes directed toward synthesis and folding of the target and 
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purification steps are not required. The cellular extract is washed through centrifugation 
steps. Membranes, some of  proteases and RNA  and others unuseful molecules are 
removed. All the purified components such as ribosomes, T7RNA polymerase and the most 
of the  components of the cytoplasm of the living source (Fig.7)   are transferred in an in 
vitro apparatus simulating living cells. 
                           
 
Fig.7: Essential components of transcription/translation machinery (Reprinted from Bernhard F.42). 
 
 
An example of apparatus is represented by a dyalisis sistem in which the dialysis 
membrane may represent the cellular membrane. (Fig.8) 
 
Fig.8: Reaction chamber assembly. Soak one 10 cm length of Spectrapor #2 dialysis 
tubing per reaction in MQ water for 5 min, then tie a knot as close as possible to one end. 
Trim the knot to have minimal overhang. Cut off the lid and hinde section of 500 μL 
Eppendorf. The lid is retained and the hinge is discarded. Removal of the hinge allows the 
tube to fit inside a 10 mL tube. The bottom 0.5 cm of the tube is then sliced off using a 
scalpel. Insert each cut Eppendorf tube into the top of a pre-tied length of dialysis tubing, 
The Eppendorf tube ensures the contents of the dialysis tube are readily accessible. Remove 
the dialysis tubing from the MQ water and insert the Eppendorf tube immediately prior to 
use, so that the tubing does not dry out before assembly of the complete reactionPipette the reaction mixture 
into the dialysis tubing and seal the Eppendorf tube with the pre-cut lid. Place the dialysis tubing inside the 10 
mL tube containing the outside buffer. The entyre assembly is then collocated at 37°C with shaking for 6-8 
hours, then the inner solution centrifugated and protein expression checked by SDS-acrylamide 
electrophoresis.  Reprinted from Appnonyi et al. 15 
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Dialysis membrane  separates the external solution that is in exchange with the inner 
solution where the protein synthesis  occurs. The outer solution contains a buffered solution 
of pH 7.5, aminoacid mix,  salts, energy - regenerating factors and  alanine for T7RNAP; 
the inner solution  has the same composition of the external buffer, but it is enriched with 
cellular extract, DNA plasmid, T7RNA polymerase plasmid (or purified T7RNA  enzyme), 
RNasin inhibitors. The continuous exchange of the reagents it was proved to increase the 
yield of protein expression when compared with old methods based on not-continuous 
exchange system 16,17. 
The reaction is allowed to proceed in a autoinducted manner18. Starting input is given by 
the bacterial T7 RNA polymerase  that it can be recovered in the cellular extract. In this 
case, T7RNA polymerase is freshly generate making the procedure cheeper and faster. 
Previously expressed and purified T7RNA polymerase is added to the reaction when 
labelled protein are expressed. In this way labelled aminoacid incorporation in T7RNA 
polymerase does not occur. 
By the moment that the system is not a living organism, many parameters and conditions 
can be directly controlled. In fact, the completely open nature of cell-free systems allows 
external molecules and components to be added to create favourable environments for 
protein folding and activities. Consequently, candidate are proteins which are toxic or 
sensitive to proteolysis in vivo 19 and proteins requiring binding partners for expression in 
soluble form20 including membrane proteins21, metals 22 or inhibitors. A cellular extract 
from E. coli containing rare codons may help the synthesis of human proteins that are rich 
in. Addition  or coexpression of trigger factors to the reaction is also possible in vitro. 
Some other parameters can be controlled and efforts to prolong the protein synthesis and to 
increase the final yield are continuously in progress 23, 24, 25. 
Cell-free protein synthesis has a great potential in structural biology, since Kigawa et al. 
demonstrated the possibility of obtaining milligram-per-mL yields in a coupled cell-free 
transcription-translation system based on E. coli cell extract26. These concentrations are 
sufficient for analysis by nuclear magnetic resonance (NMR) spectroscopy, providing a 
convenient and rapid way to analyze proteins, which would be difficult or costly to make .  
One of the most useful application is the specific labeling of proteins with isotopes , 
unnatural or fluorescence-enhanced amino acid. 27,28.  Cell-free protein synthesis uses 
isotope-labelled amino acids much more economically than in vivo expression systems and 
is much less affected by isotope-scrambling by metabolic enzymes29. Moreover, the target 
protein is the only protein synthesized during the reaction. Consequently, purification of 
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the protein by chromatography or concentration of the sample is not necessary30 and  
proteins can be made from DNA and structurally characterized within one day 31. 
Many commercial kits for high-yield cell-free protein expression have become available 
(e.g. the RTS system by Roche and the Expressway system by Invitrogen), but the daily 
cost tends to be prohibitive. An “hand-made” E. coli based cell-free protein synthesis 
protocol has been developed in the Otting’s laboratory at the Australian National 
University 15  and applied in our laboratories. 
However, exspecially for NMR purpose, which requires the production of high yield of 
labelled 15N and 13C samples, E.coli still remain the best choice. 
PP2Ac/c1 and PP6 c/c1 have been expressed as insoluble in E.coli. Cell-free protein 
sinthesys has been considered as a new approach to test the expresion and solubility of the 
target proteins. 
2.5 Protein purification follows the in vivo expression 
 
Depending on the subcellular localization of the expressed protein (e.g. periplasmic space 
or within the cytoplasm as soluble or insoluble) different purification ways can be 
performed. 
After disrupting the cells by sonication, next steps must be compatible with different 
physical, chemical and biological characteristics of the proteins,  the amount of material to 
be processed and the intended downstream applications. All the purifications involve 
several chromatographic steps. Ion exchange and size exclusion chromatography are 
commonly used to purify proteins expressed as  native. On the other hand, fusion tags 
increase the efficiency of protein purification by affinity chromatography. In particular, gel 
filtration, immobilized metal ion affinity chromatography (IMAC) and  agarose matrix 
having GST (glutathione-S-transferase) affinity have been used in PPP sample preparation.  
Generally the GST affinity for its matrix is not so strong so further purification steps are 
required. 
IMAC exploits the interaction between chelated transition metal ions like Zn2+ or Ni2+ and 
side-chains of specific amino acids (mainly histidine) on the protein . Methods used to elute 
the protein of interest include changing the pH, or adding a competitive molecule, such as 
imidazole. Excess of reduced glutathione is used to displace the GST tagged protein. 
Enzymatic digestion using a specific protease is then necessary to remove the fusion 
partner from the target protein and a second IMAC purification is generally performed in 
order to separate them. TEV, Fatt.Xa, Thrombin, Prescission Protease, recombinant 
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Enterokinase are some example of proteases that are normally used for the cleavage of 
fusion proteins.  
 
PP5 (residues 16-499)  protein has been purified by GST affinity chromatography and GST 
cutted by Prescission Protease enzyme (Amersham). A second GST affinity 
chromatography has been performed in order to separate GST-tag and the not cutted 
protein from the cutted one.  
and). A further purification step was done using  IMAC  by His-trap column charged with 
Ni2+  considering the presence of a C-terminal His-tag. Finally size exclusion 
cromatography has been performed.  
The protein sample (in Tris 50 mM, NaCl 150 mM, DTT 10 mM, ZnCl2 0.1 mM, pH 7.5) 
concentrated up to 0.25 mM, was analyzed by 1H,15N-TROSY NMR spectrum recorded at 
900 MHz. 
 
In case of PP5c (residues 169-499),  the first purification step has been performed using 
GST-affinity cromatography.  His-GST tag has been cleaved with 2ul of Ac-TEV 
protease/1mg of fusion protein (Invitrogen, Carlsbad, CA) under over night incubation at 
room temperature.The IMAC by His-trap column charged with Ni2+  purification has been 
made. The unbounded protein coming from this step represents the protein lacking the His-
GST tag. This sample has been further purified by gel filtration. Samples of the purified 
PP5 protein were dialyzed against either solutions containing MnCl2 or ZnCl2 in order to 
produce the paramagnetic protein and the diamagnetic analogue. A fast dyalisis has been 
done and  unbound metals removed. 
 
PP2A c/c1 -PP6 c/c1 
The two His-tagged proteins have been recovered in the inclusion bodies. IMAC 
purification has been performed by His-trap column charged with Ni2+. Denaturising 
conditions (urea) have been used in each purification step.  Consequently the use of Ac-
TEV protease for the removal of His-tag was not possible. In this respect different 
refolding protocols have been tested.  Precipitation of more than 90% of the sample 
occurred so that further characterizations were not allowed. 
The in vitro synthesis resulted in a insoluble expressed product for all the PPP constructs. 
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2.6 Biochemical and biophysical protein characterization 
2.6.1 Metals content determination by ICP 
Inductively Coupled Plasma (ICP) is an analytical technique used for the detection of trace 
metals and allows multi-elemental, simultaneous analysis of most elements in the periodic 
table, with excellent sensitivity (ng/L or ppt) and high sample throughput. The analytical 
principle used is optical emission spectroscopy, triggered by plasma ionization. The liquid 
sample is introduced in the prechamber, usually by mean of a peristaltic pump, then 
nebulised and entrained in the flow of plasma support gas, which is typically Argon. The 
analytes are excited into a state of radiated light emission by the plasma vapour and the 
emitted radiation is converted to an electrical signal that can be measured quantitatively by 
resolving the light into its component radiation (almost always by means of a diffraction 
grating). The light intensity is measured, at the specific wavelength for each element line, 
with a CCD (charge coupled device, basically an array of tiny, light-sensitive diodes) 
which converts it to electrical signals. The electron signal intensity is then compared to 
previously measured intensities of standard solutions of the target elements, and a 
concentration is computed. This spectroscopic technique is very suitable for the proteins 
metal content determination, since it requires very small amounts of sample, and is not 
perturbed by the polypeptidic matrix. 
Both the non-metallated and metallated samples  of PP5c (169-499)  have been then 
analyzed by ICP mass for the metal contenent.  
2.6.2 Enzymatic assay 
Although serine/threonine phosphatases participate in multiple signaling transduction 
events the actual biological substrates for most phosphatase are not known. As such, 
activity assays rely on synthetic surrogate substrates. 
Basically, activity assays for phosphatases consider the hydrolysis of a arylphosphate 
moiety from a synthetic substrate yielding a spectroscopically active product. Many 
different substrates and assays have been developed to detect the hydrolytic activity of 
protein phosphatases 32. 
Hydrolysis products that can be quantified without interfering with the reaction (continuous 
enzyme assays) are advantageous over those that require the reaction to be stopped 
(discontinuous enzyme assays) beacuse they require decreased sample manipulation 33. 
Para-nitrophenyl phosphate (pNPP) is a chromogenic substrate for most phosphatases such 
as alkaline phosphatases, acid phosphatases, protein tyrosine phosphatases and 
serine/threonine phosphatases.The reaction yields para-nitrophenol (Fig. 9).  
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Fig. 9:  pNPP Assay Principle: deprotonation of the phenolicgroup gives rise to the yellow colored              
p-nitrophenylene anion. 
 
The phenolate ion becomes an intense yellow soluble product under alkaline conditions 
that are required by most serine/threonine phosphatases. Production of pNP can be 
followed by monitoring the increase in absorbance at 405nm on a spectrophotometer in a 
continuous way. An additional advantage is represented by  the fact that serine/threonine 
phosphatses show high efficiency hydrolysis  for pNPP34. 
Consequently, progressive suppression of pNPP phosphatase activity can be monitored by 
adding competitive phosphatase inhibitors for which the binding site is the catalytic centre, 
which is also accessible to pNPP 34. The test can be applied also to check the metal 
requirement for phosphatase activity. False positive may represent one of the most 
disadvantage in colorimetric assay.Consequently, the assay can be utilized as a simple and 
preliminary approach for  ligand screening studies. 
The activity of  catalytic PP5c has been tested at 25C° using p-nitrophenyl phosphate 
(pNPP) in Cary 50 Eclypse Spectrophotometer. Activity was expressed as Unit according 
to the Jena Bioscience manufacturing (Unit definition: amount of the phosphatase required 
to relase 1 mol of phosphate from pNPP in one minute at 25°C). 
The larger enzymatic activity of catalytic manganese-loaded PP5 versus the catalytic zinc-
loaded protein suggests a physiological role for the paramagnetic ion. This result further 
supports the use of the manganese-loaded PP5 in ligand selection and optimization that is 
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also based on the knowledge of the protein structure. Specific protein-ligand interaction can 
be investigated, increasing efforts in structure-based drug discovery. 
2.7 Structural characterization 
In order to understand completely the function of a protein, the determination of the 3D 
structure is of basic importance. X-ray crystallography and NMR spectroscopy are the two 
main techniques that can provide structures of macromolecules at atomic resolution. Both 
techniques are well established and play a key role in Structural Biology as a basis for a 
detailed understanding of molecular functions. Their respective different advantages and 
disadvantages in terms of sample preparation and data collection and analysis make these 
two approaches complementary in Structural Proteomics.   
Additionally, relaxometry can provide structural and dynamical information on 
diamagnetic and paramagnetic biomolecules.  
2.7.1 Structural determination by NMR spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy is unique among the methods available 
for 3D- structure determination of proteins at atomic resolution, since the NMR data can be 
recorded in solution, simulating a phisiological state of the protein. An highly purified 
protein sample is required and in homogeneous preparation and/or aggregation of the 
protein as well as low molecular weight impurities may be harmful in structural  
determination. Limiting factors in NMR spetroscopy still remain the long time request for 
the data analysis as well as the size limit of protein that is  currently around 35KD.  Recent 
advances in both hardware and experimental design promise to allow the study of much 
larger protein 35. 
 
PP5 (16-499) 
The protein sample (in Tris 50 mM, NaCl 150 mM, DTT 10 mM, ZnCl2 0.1 mM, pH 7.5) 
concentrated up to 0.25 mM, was analyzed and folding checked by 1H,15N-TROSY NMR 
spectrum recorded at 900 MHz  
PP5c (169-499) 
The protein sample (in Tris 50 mM, NaCl 150 mM, DTT 10 mM, MnCl2 0.1 mM, pH 7.5), 
concentrated up to 0.3 mM, was analyzed by 1H,15N-TROSY NMR spectrum recorded at 
700 MHz. 
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2.7.2 Proton relaxometry 
 
Proton relaxometry can be applied to provide structural and dynamical informations on 
biomolecules containing a paramagnetic metal in the active site 36 The paramagnetic 
relaxation enhancement experienced by proton nuclei is mainly influenced by a direct 
interaction of the solvent molecules with the metal ion 37. In this case, the relaxation rate of 
solvent nuclei can act as a probe to monitor the solvent accessibility to the paramagnetic 
center. Several pharmaceutical targets are metalloproteins, where a diamagnetic or 
paramagnetic metal ion plays a catalytic function. Many commercial drugs inhibits these 
pathologically relevant metalloenzymes interacting directly with the catalytic metal ion or 
preventing the access of the physiologic substrate to the active site38. In most of the case, 
the interaction of the solvent molecules with the metal ion is also prevented by the ligand 
binding. Therefore relaxometry can be exploited in drug discovery to monitor the 
interaction of ligands at the metal binding site. Moreover, a relaxometric investigation 
performed on already identified ligands permits a rapid selection of the molecule for their 
ability to bind the catalytic pocket. 
The presence of two metal  in the catalytic pocket of PP5 in the is revealed by X-ray 
analysis39,40.  The possibility to achieve a metallated form of PP5 with the paramagnetic 
Mn[II] make PP5c suitable for this kind of validation. Moreover inhibition of its 
phosphatase activity can be efficiently achieved by blocking the catalytic channel with 
small ligands 41. Cantharidin, a biologically active natural compound, is one of the  
prototypes of this class of inhibitors. The binding of cantharidine and of two structurally-
related compounds to PP5 has been here investigated with relaxometry. 
Both autoinhibitory and catalyic domains have a strong potential for modulating 
phosphatases activity by the interaction with targeted molecules. 
This methodology is can be  also applied on authoinhibithed form of PP5 with the aim to  
test the bind of both already known and hypotized activators. 
 
All the protein samples (50 µM) in a buffer containing Tris 50 mM, NaCl 150 mM, DTT 
1mM, at pH 7.5 were analysed by relaxometer at 298 K. The NMRD profiles were 
collected with a Stelar fast field cycling relaxometer in the 0.01–40 MHz proton Larmor 
frequency range. 
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2.7.3 X-ray and protein crystallization 
 
X-ray crystallography enables to visualize protein structures at the atomic level and 
enhances our understanding of protein function. Specifically it is possible to study how 
proteins interact with other molecules, how they undergo conformational changes, and how 
they perform catalysis in the case of enzymes. In all forms of microscopy, the amount of 
detail or the resolution is limited by the wavelength of the electro-magnetic radiation used. 
In order to see proteins in atomic detail we need to work with electro-magnetic radiation 
with a wavelength of around 0.1 nm or 1 Å. 
The diffraction from a single molecule would be too weak to be measurable. So it is 
necessary to use an ordered three-dimensional array of molecules, in other words a crystal, 
to magnify the signal. Even a small protein crystal might contain a billion molecules. If the 
crystal is well ordered, then diffraction will be measurable at high angles or high resolution 
and a detailed structure should result. The X-rays are diffracted by the electrons in the 
structure and consequently the result of an X-ray experiment is a 3-dimensional map 
showing the distribution of electrons in the structure.  
X-ray studies usually require substantial investment of time in order to optimize the 
crystallization conditions and obtain a crystal with good diffraction properties. This process 
can take weeks or months, but once a well-diffracting (<2.5Å) crystal is obtained, the 
structure determination can proceed quite quickly. In order to crystallize a protein, the 
purified protein undergoes slow precipitation from an aqueous solution. As result, 
individual protein molecules align themselves in a repeating series of "unit cells" by 
adopting a consistent orientation. The crystalline “lattice” that forms is held together by 
non-covalent interactions. The non-covalent bonds that hold together the lattice are often 
formed through several layers of solvent molecules. The production of good crystals is 
dependent upon a number of environmental factors because so much variation exists 
among proteins, with each individual requiring unique conditions for successful 
crystallization. Especially protein purity and pH conditions are very important; for example 
different pH values can result in different packing orientations.  
The two most commonly used methods for protein crystallization are both vapor diffusion 
techniques. These are known as the “hanging drop” and “sitting drop” methods. Both entail 
a droplet containing purified protein, buffer and precipitant being allowed to equilibrate 
with a larger reservoir containing similar buffers and precipitants in higher concentrations. 
Initially, the droplet of protein solution contains an insufficient concentration of precipitant 
for crystallization, but as water vaporizes from the drop and transfers to the reservoir, the 
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precipitant concentration increases to a level optimal for crystallization. Since the system is 
in equilibrium, these optimum conditions are maintained until the crystallization is 
complete. 
In the past few years macromolecular crystallography has become a standard technique 
used by many pharmaceutical and biotechnology companies. This methodology offers 
details of protein-ligand interactions at levels of resolution virtually unmatched by any 
other technique, and this approach holds the promise of novel, more effective, safer and 
cheaper drugs. Although crystallography remains a laborious and rather expensive 
technique, remarkable advances in structure determination and structure based drug design 
(SBDD) have been made in recent years. 
 
Crystals of PP5c were obtained using the vapour diffusion technique at 289 k from 
solutions containing MPD 40% and PEG MME 5000 20%. Crystals of the protein dialyzed 
against Mn2+ (PP5-2Mn) and from the protein dialyzed against Zn2+ (PP5-2Zn) have been 
obtained. The final protein concentration was in all cases 1.1 mM. Complexes of PP5c with 
cantharidin and structural analogues have been obtained by socking tecnique. The 
experimantal structures have been provided insight into the structural determinats 
responsible of the ligand binding. 
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Abstract 
Three forms of the catalytic domain of Human Protein Serine/Threonine Phosphatase PP5 
have been characterized. The form containing a monometallic center is catalytically 
inactive and anomalous dispersion data suggest that a manganese ion is present at the 
catalytic site. The other two forms contain one a Mn-Mn bimetallic center and the other a 
Zn-Zn center. The former is fully active while the Zn-Zn form is virtually inactive, thereby 
suggesting a possible biological role of the two metal ions in the regulation of PP5 activity. 
The three-dimensional structure of the enzyme has provided insight into the 
characterization of the nuclear metal site. 
 
Introduction 
Protein phosphatases reverse the function of their most known counterpart. These enzymes 
are involved in the hydrolysis of various phosphate esters and include acid and alkaline 
phosphatases, exonucleases, nucleotidases, diadenosine tetraphosphatases, cyclic 
nucleotide phosphodiesterases, sphingomyelin phosphodiesterases, the eukaryotic 
serine/threonine protein phosphatases, and a protein phosphatase from bacteriophage . 
They can be classified into three groups on the basis of sequence, structure and catalytic 
mechanism. The first group comprises the classic Ser/Thr phosphatases: the large 
phosphoprotein phosphatase (PPP) family (PP1, PP2A, PP2B, PP4, PP5, PP6 and PP7) and 
the protein phosphatase, Mg2+ or Mn2+ dependent (PPM) family (PP2C). The protein Tyr 
phosphatase (PTP) superfamily forms the second group, and the third group consists of the 
Asp-based protein phosphatases with a DXDXT/V catalytic signature1. Human protein 
phosphatase 5  (PP5) is a member of Serine/Threonine Phosphatases  that dephosphorylates 
their substrate in serine and threonine residues. PP5 posses a series of three N-terminal 
TPR domains that function to keep the enzyme inactive and that make PP5 unique in its 
structural features2,3. Structural analysis of human PP5 showed that the mechanism of TPR 
inhibition of the phosphatase domain is similar to the mechanism of inhibition of PP2B by 
its C-terminal regulatory segment and to that of PP1 by toxins. The enzyme is cytoplasmic 
and nuclear in both humans and S. cerevisiae, and the C-terminus contains a conserved 
sequence that is required for nuclear localization 4,5. 
PP5 is involved in regulation of rRNA transcription; it promotes cellular proliferation by 
binding to Hsp90; it promotes progression into S-phase and regulates progression through 
mitosis by binding to CDC16 and CDC27 of the anaphase-promoting complex, thus it is 
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assumed it has an effect on the development of cancer cells and Alzheimer’s diseases 5-7. 
PP5 can be considered as a promising therapeutic target for the treatment of many diseases. 
The catalytic domain of PP5 (PP5c) shares 35–45% sequence identity with the catalytic 
domains of other PPP phosphatases, including protein phosphatase 1 (PP1), 2A (PP2A), 
2B/calcineurin (PP2B), 4 (PP4), 6 (PP6), and 7 (PP7). As all the serine/threonine 
phosphatases, PP5 is a  metalloprotein. Three motifs (DXH(X)nGDXXD(X)mGNHD/E) 
highly conserved in the catalytic domain of all phosphatases8 contain most residues which 
coordinate metal ions in the active centre and are considered as the signature of the 
phosphatase family 5,9. The X-ray structures of others related phosphatases (Protein 
phosphatase 1 and Protein phosphatase 2B)  indicate that the phosphoesterase motif is 
represented as a β-α-β-α-β secondary element that provides the framework for an active site 
dinuclear metal cofactor 10. The high degree of sequence conservation within the 
phosphoesterase motif in this family of enzymes suggests that other members will share a 
common active site architecture and catalytic mechanism. The bacteriophage  protein 
phosphatase is a metal requiring enzyme by demonstrating that Mn2+ and Ni2+ are 
necessary for activation of the enzyme 10.   protein phosphatase can be reconstituted to 
contain a dinuclear Fe3+-Fe2+ center, analogous to the Fe3+-Zn2+ and Fe3+-Fe2+ centers of 
purple acid phosphatase further advancing the hypothesis that enzymes containing the 
phosphoesterase motif utilize an active site dinuclear metal center 10. The identity of the 
physiological metal ion cofactors for most phosphoesterases is still unknown, but a  Fe3+-
Zn2+, Mn 2+/Fe 2+ and Mn2+/Mn2 metal center was identified in PP2B11, PP1 and PP2A 
respectively10. Nevertheless, calcineurin phosphatase activity can be enhanced by the 
presence of a divalent metal ion, with Mn2+ and Ni2+ providing the highest level of 
activation 10. The mechanism for activation is not known, but in PP2A the addition  of a 
divalent metal such as Mn2+ appears to prevent a time-dependent inactivation process that 
may involve metal substitution12. 
X-ray crystal structure of PP1 and PP2B revealed in their catalytic subunit  a metal-bound 
water molecule acting as a nucleophile to attack the phosphorus atom of a phosphate group 
in a SN2 mechanism. Metals assist in this catalysis as Lewis acids. Protein phosphatase 2C  
too contains binuclear metal ions (2 Mn2+) in its catalytic site that promote protein 
dephosphorylation by activation of water molecules to catalyse hydrolysis in a single-step 
reaction. 3. The presence of two metal  in the catalytic pocket of PP5  is revealed by X-ray 
analysis3,13 elucidating the catalytic mechanism of action also for PP5 .From this structure 
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the authors propose a mechanism for PP5-mediated hydrolysis of phosphoprotein 
substrates, which requires the precise positioning of two metal ions within a conserved 
Asp271-M1:M2-W1-His427-His304-Asp274 catalytic motif (where M1 and M2 are metals and 
W1 is a water molecule ) 3,13. The importance to investigate the nature of the metal center in 
PP5 is also due to the fact that metal-substitution studies on this enzyme have shown that 
manganese ion can be replaced by zinc with loss of activity 3,14. This observation suggest a 
physiological role of manganese for PP5. The presence of manganese in the catalytic 
pocket of related phosphatases is also reported 15. 
Structural analysis of both the Mn-Mn and Zn-Zn enzyme have been  provided insight into 
the structure of this metal center. The catalytic domain of human PP5 (residues 169-499) 
has been here investigated.  
 
Materials and Methods 
The catalytic domain of PP5 (PP5c ) was expressed by using Gateway tecnology as His-
GST-binding fusion protein. The Gateway expression vector pDEST30 was used to 
transform  E. Coli BL21 (DE3) RIPL strain. PP5c was purified by Glutathione Sepharose 
affinity chromatography (Amersham). The His-GST tag was removed by the  TEV protease 
digestion according to the Invitrogen manifactures. The cutting leaves  four vector-derived 
amino acid residues (Gly-Ser-Phe-Thr)  at the N-terminus of PP5c. Ni2+-saturated HiTrap 
Chelating  column (Amersham) and  Superdex 75 26/60 size exclusion chromatography 
(Amersham) were used to further purify the sample. Protein sample was concentrated to 
0,1mM  as determined by Bradford assay and UV spectrophotometer. Then, a fraction of a 
sample was dialyzed against 50mM Tris-Hcl,pH 7.5, 150mM NaCl, 1mM DTT and 0.2mM 
MnCl2; an other fraction was dialyzed in the same buffer  containing ZnCl2 instead of 
manganese. The rest of the sample was in  50mM Tris-Hcl,pH 7.5, 150mM NaCl, 1mM 
DTT. Dialysis have been made in the ratio 1mL of protein per liter of solution and leaved 
to proceed for 6 hours. A second dialysis was performed in the same way. The last dialysis 
has been done in 4 hours in a metal-free solution to remove excess of the metal and 
samples have been analyzed by ICP-mass.  
Activity has been  tested against p-nitropenyl phosphate (pNPP) according to the  Jena 
Bioscience protocols and expressed as Unit/µg enzyme were one unit is the amount of the 
phosphatase required to release 1 nmol of phosphate from pNPP in one minute at 298 K 
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under the tested assay conditions. A pNPP molar extinction coefficient of 17.8 µL·nmol-
1·cm-1 was considered.  
All the protein samples have been then concentrated until 1.1mM . Crystals of PP5 were 
obtained using the vapour diffusion technique at 289 k from solutions containing 10mM 
Tris-HCl pH 8.0, MPD 40% and PEG MME 5000 20%. 
The PP5-2Mn dataset and the PP5-2Zn were measured in-house, using a PX-Ultra copper 
sealed tube source (Oxford Diffraction) equipped with an Onyx CCD detector, whereas the 
non-dialyzed PP5 was measured using synchrotron radiation at BM16 beamline (ESRF, 
Grenoble, France). All datasets were collected at 100 K and the crystals used for data 
collection were cryo-cooled without any cryo-protectant treatment. 
The data were processed in all cases using the program MOSFLM16 and scaled using the 
program SCALA17with the TAILS and SECONDARY corrections on (the latter restrained 
with a TIE SURFACE command) to achieve an empirical absorption correction. Table 1 
shows the data collection and processing statistics for all datasets.  
 
Table 1. Data collection and refinement statistics. 
 PP5 PP5-2Mn PP5-2Zn 
Spacegroup P41212 C2 C2 
Cell dimensions (Å, °) a=b= 67.99 
c= 200.62 
 
a= 154.34 
b= 41.65 
c= 105.67 
β= 96.85 
a= 154.25 
b= 41.68 
c= 106.09 
β= 96.46 
Resolution (Å) 34.5 – 2.0 38.2 – 2.0 38.3-2.6 
Unique reflections 32495 (4530) 45387 (6419) 19742 (2660) 
Overall completeness (%) 99.0 (97.7) 99.3 (97.3) 93.3 (87.2) 
Rsym (%) 10.0 (69.4) 17.3 (31.4) 21.1 (45.3) 
Multiplicity 11.7 (4.0) 4.4 (2.8) 3.9 (3.2) 
I/(σI) 19.8 (1.6) 8.4 (4.1) 5.8 (2.7) 
Wilson plot B-factor (Å2) 27.94 0.9 13.2 
Rcryst  / Rfree (%) 19.8 / 25.9 21.6 / 27.7 19.9 / 29.1 
Protein atoms 2596 5058 5058 
Water molecules 194 306 56 
Ions per monomer 1 2 2 
RMSD bond lengths (Å) 0.031 0.030 0.052 
RMSD bond angles (º) 2.57 2.35 3.70 
Mean B-factor  (Å2) 39.03 2.93 3.08 
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The structures were solved using the molecular replacement technique; the model used for 
all datasets was 1S95, where water molecules and ions were omitted from the models. The 
correct orientation and translation of the molecule within the crystallographic unit cell was 
determined with standard Patterson search techniques 18,19,19 as implemented in the program 
MOLREP20,21. 
The isotropic refinement was carried out using REFMAC5 22 on all datasets. REFMAC5 
default weights for the crystallographic and the geometrical term have been used in all 
cases. 
In between the refinement cycles the models were subjected to manual rebuilding by using 
XtalView 23. Water molecules have been added by using the standard procedures within the 
ARP/WARP suite 24. The stereochemical quality of the refined models was assessed using 
the program Procheck.25 The Ramachandran plot is in all cases of good quality.  
 
Results and Discussion 
 
PP5 is involved in signaling pathways that control cellular responses to stress, 
glucocorticoids and DNA damage. The catalytic domain of PP5 (PP5c) shares 35-45% 
sequence identity with the catalytic domain of other PPP phosphatases. This enzyme is 
sensitive to inhibition by okadaic acid, microcystin, cantharidin, tautomycin and calyculin 
A. PP5 is a two domains protein since it is formed by a catalytic domain and by an 
extended N-terminal domain containing three tetratricopeptide repeat (TPR) motifs. The 
TPR domain acts as an interface for protein-protein interactions and provides a means of 
targeting PP5 to particular regions within the cell and facilitating interactions with 
substrates. The TPR domain engages with the catalytic channel of the phosphatase domain, 
restricting access to the catalytic site. 
All the members of the phosphatase family share a common phosphoesterase motif and an 
active site dinuclear metal center. Despite these similarities in sequence, each phosphatase 
in the family appears to have different metal ion requirements. The hallmark of 
metallophosphatases is a dinuclear center with separation between metal ions from 3.1 to 
3.4 Å.  The catalytic site of PP5, as obtained in a recent work 13 (PDB code: 1S95) and by 
us, can be identified from the position of these two metal ions. It is located at the base of a 
shallow depression on the surface formed by the residues of four loops (Fig.1). Anomalous 
dispersion from non-dialyzed PP5 crystals revealed the presence of a Mn2+ in a 
mononuclear binding site (see below) but the presence of Fe2+ or Zn2+ cannot be ruled out. 
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The presence of manganese, iron and zinc in the protein sample has been also revealed by 
ICP-mass (data not shown). X-ray fluorescence and anomalous dispersion from PP5 
crystals obtained from the protein dialyzed against Mn2+ (PP5-2Mn hereafter) revealed the 
presence of two Mn2+ ions in the metal site. On the other hand, X-ray fluorescence and 
anomalous dispersion from PP5 crystals obtained from the protein dialyzed against Zn2+ 
(PP5-2Zn hereafter) revealed the presence of two Zn2+ ions in the metal site. The structures 
of PP5-2Mn and PP5-2Zn have an RMSD of 0.21 Å, and the catalytic sites are perfectly 
superimposable (Fig. 2A). 
 
 
Fig.1 Ribbon representation of  the crystallization unit of the catalytic domain of PP5 in complex with 
manganese ions (Green spheres). The figure was generated with PyMol.. 
 
 
Nevertheless, PP5-2Zn shows no catalytic activity against the pNPP substrate, while PP5-
2Mn retains full enzymatic activity. The affinity constant of manganese for PP5 was found 
to be around 10µM. This value  has been obtained by pNPP enzimatic assay. Interestingly, 
the incubation of the zinc-loaded PP5 with different concentration of Mn(II) did not 
increase the activity of the protein, thereby suggesting a larger affinity of PP5 for zinc ion. 
In this work we refer to the metal ions as M1 and M2, based upon the coordinating 
residues. Each metal ion is coordinated by five ligands (Fig. 2B), with the bridging 
carboxylate oxygen of Asp271 and a water molecule (W1) coordinating both M1 and M2. 
Asp242, His244 and W2 also coordinate M1, and Asn303, His352 and His427 coordinate 
M2. The metals are 3.3 Å apart. This metal binding site corresponds to the one already 
reported in literature13 where a phosphate ion provides an additional oxygen atom as a 
ligand for both metals. Interestingly, the structure of the non-dialyzed PP5 obtained in the 
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present work is quite different from the one already present in literature and from both PP5-
2Zn and PP5-2Mn. 
The non-dialyzed protein crystallizes in the space group P41212 with one molecule in the 
asymmetric unit, at variance with 1S95, PP5-2Zn and PP5-2Mn, which belong to space 
group C2 with two molecules in the asymmetric unit. 
The catalytic site of non-dialyzed PP5 has only one metal, namely M2, which shows a 
similar coordination to the one in PP5-2Zn and PP5-2Mn, where M1 is replaced by a water 
molecule (see Fig.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Superimposition of crystal structure of  not-dialyzed PP5 (Red) and PP5-2Zn (Blue).  A monometallic 
center is present at the catalytic site of not-dialyzed PP5. Differently,  the metal-loaded PP5 contains a binuclear 
metal center. 
 
M1 M2 
Asp271
Asp242
His244
Water His427 
Asn303 
His352 
Fig. 2 Crystal structures of PP5-2Mn (Blue) and PP5-2Zn (Green). Superimposition of the two 
structures shows that no structural differences are appreciated (A). The ligands that coordinates the metal 
ions are shown in B. 
M1
M2
Asp271
W1
Asp242
His244
W2
His427His352
Asn303
A B
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The structures of PP5-2Mn and non-dialyzed PP5 have an RMSD of 0.29 Å, and the same 
RMSD is found between the structures of PP5-2Zn and non-dialyzed PP5. The different 
crystal packing and the lack of a metal in non-dialyzed PP5 is certainly due to the presence 
of the C-terminal of another molecule belonging to another asymmetric unit in the catalytic 
site. The C-terminal of PP5 is actually present in the active site in the auto inhibited form 
of the protein, as described by  Yang et al.3. In the dialyzed protein the presence of the two 
ions in the active site hinders the interaction with the C-terminal of another adjacent 
molecule in such a way that the last ten residues are not stabilized by any interaction: they 
are therefore extremely mobile and do not show any visible electron density. 
It has been proposed a catalytic mechanism for PP5 in which the nucleophile is a bridging 
hydroxide ion ligated to both metal ions in the active site and the leaving group oxygen 
does not coordinate an active site metal. In the proposed metal-ion mediated hydrolysis of 
phosphorylated substrates, one bridged hydroxide serves as the nucleophile that attacks the 
phosphorus atom of the substrate.It has been proposed13 that is is W1 that provides the 
bridging hydroxide which serves as the nucleophile attacking the phosphorous atom of the 
subtrate phosphoryl moiety. 
The interaction of W1 with His427 and the dinuclear metal center helps fix the orientation 
of a lone pair of electrons from the hydroxide W1 toward the phosphorous atom, thereby 
helping to reduce the entropic barrier for nucleophilic attack. 
 
Conclusions 
 
The biochemical and structural characterization of the binuclear active site of PP5 has 
provided relevant information on the nature and on the role of the metal ions responsible 
for the catalytic activity of the enzyme. The ICP analysis and partially the X-ray 
investigation revel that manganese,  iron, zinc and can be present at the catalytic site. A 
full-loaded forms of the protein with manganese or zinc have been prepared by exhaustive 
dialysis in presence of submillimolar concentration of the metal ion in solution. However, 
only the protein containing manganese exhibits full enzymatic activity suggesting a 
possible roles for these two metal ions in the regulation of PP5 function. In this respect also 
the different affinity for PP5, observed for the two metal ions, could play a crucial role. 
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Crystal structure of Cantharidin with the catalytic domain of Human 
Serine/Threonine Phosphatase PP51 
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Abstract 
Human Protein Serine/Threonine Phosphatase PP5 is inhibited by a number of natural 
toxins13 However, the binding modes of these inhibitors with PP5 are unknown. To 
elucidate the binding mode of  selected inhibitors to PP5, it is necessary to determine the 
three-dimensional structure of their complex. Among  well known PPP inhibitors, 
cantharidin, cantharidic acid and endothal have been selected in this study. Their low 
molecular weight may facilitate a further structure –based drug design. The crystal 
structures of the catalytic domain of PP5 in complex with cantharidin, cantharidic acid and 
endothal have been solved, providing interesting  informations on the determinants 
responsible of the binding. 
 
Introduction 
The reversible phosphorylation of serine/threonine residues in proteins has been known to 
play a crucial role in cellular signal transduction. Protein-serine/threonine phosphatases 
(PPP) which catalyze the reverse reaction of kinases , comprise protein phosphatase 1, 2A, 
2B, 4, 5, 6, 7 and 2C. PP1, PP2A ,PP2B, PP4, PP5, PP6 and PP7 have highly homologous 
catalytic domains but differ in their substrate specificities and interactions with regulatory 
molecules, whereas PP2C shares no sequence homology to the others1. 
The crystal structures of the catalytic subunits of PP1, PP2A, PP2B and PP5 were recently 
solved. These structures revealed a common motif containing a dinuclear metal ion center 
located at the active site and every active site residue involved in metal coordination or 
implicated in catalysis is strictly conserved2. 
PP5 differs from PP1-PP7 in that it contains an N-terminal domain characterized by the 
presence of three tetratricopeptide repeats which posses an authoinhibitory funciton and 
mediate protein protein interaction. Moreover, a flexible linker region connects the N-
terminal domain to the catalytic domain that is strickingly similar to that of the catalytic 
subunit of other related phosphatases. A C-terminal subdomain helps to mantein a closed, 
inactive conformation by stabilizing the N-terminal domain over the catalytic site, thereby 
blocking the substrate access 3,4. 
Recent findings suggest the interaction of PP5 with critical substrates is regulated by 
cellular stress5. PP5 is required for activation of the DNA-damage-activated protein kinase. 
Both knock down of PP5 by antisense and overexpression of catalytically inactive 
phosphatases attenuated activation of ATM by ionizing radiation and allowed DNA 
synthesis in the presence of radiation damage Hypoxia, oxidative stress and rapamycin 
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induce apoptosis in sensitive cell lines in a pathway that requires activation of the apoptosis 
signal regulated kinase 1 (ASK1). Several recent reports suggest that PP5 regulates ASK1-
dependent apoptosis and may promote tumor growth. PP5 binds to and inhibits ASK1, 
blocking activation of MKK4 and JNK Over-expression of PP5 represses ASK1 activation, 
blocks apoptosis after hypoxia and promotes tumor growth in a MCF-7 mouse xenograph 
model [Rapamycin inhibits the activity of the protein kinase mTOR and induces a stress 
response that includes activation of ASK1. In sensitive cells this results in apoptosis. ASK1 
activation correlated with PP5 inhibition or depletion, and over-expression of PP5 
prevented ASK1  
activation and blocked apoptosis in a rhabdomyosarcoma cell line Hence, one major role of 
PP5 seems to be regulating the activation of stress and DNA-damage-regulated protein 
kinases. PP5 is assumed it has also an effect on the development of cancer cells and 
Alzheimer’s diseases5-7. Consequently, PP5 is a promising therapeutic target in the 
treatment of many diseases. Removal of the N-terminal domain leads to the activation of 
PP5 8. Successful development of drugs may require targeting of the phosphatase domain 
even though in some cases PP5 is needed 9. 
The structural features of the PP5 were reveled by the high resolution X-ray analysis 4. In 
particular, the structure of PP5 catalytic domain shows that the essential catalytic motif 
contains six conserved features: Asp274, His304, Asp271, the backbone carbonyl of 
His427, the two active site metal ions (M1 and M2), and W1 (water/hydroxide coordinated 
to the two active site metal ions). Sequence alignments and comparisons to other crystal 
structures reveal that this motif is common to all members of the PPP family phosphatases, 
as is the hydrogen bond network that ensures this catalytic activity. Structure-based 
sequence alignment of PP5 with the eukaryotic PPP family members reveals an active site 
motif consisting of ten conserved amino acids, Asp242-Xaa243-His244-Xaa26–27-Asp271-
Xaa272-Xaa273-Asp274-Arg275-Xaa28-Asn303-His304-Xaa48-His352-Xaa48–54-Arg400 Xaa27-
His427. Six of these amino acids act as metal-coordinating residues (Asp242, His244, Asp271, 
Asn303, His352, and His427), and four (Arg275, Asn303, His304, and Arg400) help position the 
phosphate ion through hydrogen bonds to O1, O2, O3, and O4 4. The arginine residues along 
with His304 when protonated and the metal ions create the only large pocket of positive 
electrostatic potential on the surface of PP5c. 
The dinuclear metal site is situated in a unique protein fold, a β-α-β-α-β motif which 
provides the majority of ligands to the metal ions10. A similar fold is also seen in plant 
purple acid phosphatases, which also contain a dinuclear iron–zinc cofactor. In these 
enzymes, the two metal ions are bridged by a solvent molecule and a carboxylate group 
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from an aspartic acid residue, juxtaposing the two metal ions. A similar motif has been 
identified in a number of other enzymes which exhibit phosphoesterase activity, 
implicating several of them as metalloenzymes which contain dinuclear metal ion 
cofactors10. In the catalytic site of PP5, each metal ion is coordinated by six ligands in a 
slightly distorted octahedral geometry, with the bridging carboxylate oxygen of Asp271 
and W1 each coordinating both M1 and M2 Asp242, His244, W2, and O1 of the phosphate 
ion also coordinate M1, and Asn303, His352, His427, and O2 of the phosphate coordinate 
M2. The phosphate ion coordinates the metal ions in a bidentate mode, indicating that the 
close spacing of the metal ions is necessary for catalysis.. The nature of the metal ions 
present at the active site has been longely debuted. The biochemical characterization 
performed on the purified protein showed that Mn, Zn as well as Fe can be present at the 
catalytic site.  
The larger enzymatic activity of Mn(II)-PP5 versus the Zn(II)-loaded protein suggests a 
physiological role for the manganese ion 11. 
The necessary alignment of substrate and nucleophile is facilitated by substrate contacts 
with M1, M2, Arg275, Asn303,His304, and Arg400 and interactions of W1 with M1, M2, 
and His427. Thus, there are many sites for inhibitor binding that should disrupt catalytic 
activity5. Despite this, the development of a specific inhibitor may be challenging, as the 
catalytic core of PP5 is highly homologous to other eukaryotic PPP family phosphatases. In 
addition, both structural and mutational studies indicate that PP1, PP2A, PP2B and PP5 
share a common catalytic mechanism that is most likely common to the whole PPP family5. 
Superposition of the structure of PP5c onto the structures of other eukaryotic PPP 
phosphatases such as PP1, PP2A and PP2B gives root mean square deviations of <2.0Å 
within the highly homologous ~270-residue region used in the calculations. Nevertheless, 
comparisons of the loop regions of PP5, PP1, PP2A and PP2B reveal significant variation 
that may be relevant for drug discovery efforts, such as sequence/conformational 
differences in the β12/β13 loop that plays an important role in microcystin-LR and okadaic 
acid-mediated inhibition of catalytic activity5. Such structural differences closely apposed 
to the conserved catalytic site suggest the feasibility of developing type-specific inhibitors5. 
Many commercial drugs inhibits this pathologically relevant metalloenzyme interacting 
directly with the catalytic metal ion or preventing the access of the physiologic substrate to 
the active site 12,13. To date several compounds that inhibit the activity of PP5 have been 
identified (i.e.  okadaic acid, microcystins, cantharidin, calyculin A, tautomycin and 
fostriecin)13. Most of these compounds were originally derived from extract of natural 
products, and many were initially identified as eukaryotic cell toxins. The organisms that 
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make these inhibitors are biologically diverse, with potent inhibitors produced by 
dinoflagellates (i.e. okadaic acid), cyanobacteria ( i.e. variants of microcystin and 
nodularin), Streptomyces (i.e. tautomycin and fostriecin) and insects (cantharidin). The 
ultimate natural source of calyculin A, a potent inhibitor identified from a marine sponge 
extract, is still unknown. PP5 is sensitive to inhibition of okadaic acid, microcystins, 
calyculin A ,tautomycin cantharidin at nanomolar concentrations 11,14. 
Cantharidin (exo. exo-2. 3-dimethyl-7-oxobicyclo [2.2.1] heptane-2,3-dicarboxylic acid 
anhydride), is a major component of the Chinese blister beetles: Mylabris phalerata or Al. 
cichorii). The dried body of these beetles has been used by the Chinese as a natural remedy 
for the past 2000 years. Although Western medicine decreed cantharidin to be too toxic in 
the early 1900's. Its purported aphrodisiac qualities (the active ingredient of"Spanish Fly"), 
and its widespread occurrence in cattle feed still results in numerous human and livestock 
poisonings15. The cellular mechanisms underlying the toxicity of cantharidin have been 
under investigation for several years. Cantharidin interfers with mitochondrial respiration 
and  was then shown to bind with high affinity to a specificand saturable binding site in a 
cytosolic fraction produced from mouse liver. This high-affinity cantharidin binding site 
was subsequently identified in several other tissues including heart. kidney, lung, pancreas, 
kin. spleen, brain, blood and stomach. 
Due to its low molecular weight, cantharidin can be considered as a lead to indentify  
structural determinants of the binding mode for a selective design of drugs against PP5. 
In recent years, there has been intense interest in the development of potent and selective 
inhibitors of the serine/threonine class of protein phosphatases, PP1 and PP2A. These 
attempts have included analogues of cantharidin 16 and the more complex toxins such as the 
microcystin which resulted in moderate PP1 selectivity 17. 
Of all the known naturally occurring toxins, cantharidin represents by far the simplest 
synthetic target. The synthesis of numerous analogues of cantharidin, and their inhibition of 
PP1 and PP2A is reported 18. 
Here the catalytic domain of PP5  in complex with the inhibitors cantharidin, cantharidic 
acid and endothal has been investigated. Crystal structure of PP5 complexed with these 
molecules has been solved revealing interesting feautures in the binding mode that support 
further structure-based drug-design.  
 
Materials and methods 
The catalytic domain of PP5 corresponding to the construct 169-449 has been cloned in the 
expression vector pDEST30 by Gateway technology and expressed in soluble form in E. 
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Coli BL21(DE3) RIPL. The growing conditions were optimized in fermenters and the 
GST-fused protein has been purified by means of both affinity and size exclusion 
chromatography after the removal of the tag. 
Samples of the purified PP5 protein were dialyzed against a solution containing MnCl2 in 
order to produce a Mn-Mn enzyme. ICP was performed to verify the metal content. The 
enzymatic activity of the dialyzed  sample has been assayed by monitoring the 
dephosphorylation of the p-nitro-phenol-phosphate (pNPP) substrate. The inhibition of 
dephosphorylation of pNPP was monitored  after the addition of selected compounds to the 
reaction misture. 
 
Crystals of the 2Mn-PP5  (1.1mM) were obtained using vapor diffusion technique at 16°C 
from a solution containing 10mM Tris-HCl pH 8.0, 40% MPD and 20% PEG MME 5000. 
Crystals of PP5-2Mn in complex with the inhibitors endothal, cantharidin and cantharidic 
acid were obtained through soaking PP5-2Mn crystals with the mother liquor containing 
the inhibitor itself. 
The PP5-2Mn complexed with cantharidin, cantharidic acid and endothal were acquired at 
beamline ID23-1 (ESRF, Grenoble, France). 
All datasets were collected at 100 K and the crystals used for data collection were cryo-
cooled without any cryo-protectant treatment. 
The data were processed in all cases using the program MOSFLM19 and scaled using the 
program SCALA20 with the TAILS and SECONDARY corrections on (the latter restrained 
with a TIE SURFACE command) to achieve an empirical absorption correction.  
The structures were solved using the molecular replacement technique; the model used for 
all datasets was 1S95, where water molecules and ions were omitted from the models. The 
correct orientation and translation of the molecule within the crystallographic unit cell was 
determined with standard Patterson search techniques 21,22,22  as implemented in the 
program MOLREP23,24. 
The isotropic refinement was carried out using REFMAC5 25 on all datasets. REFMAC5 
default weights for the crystallographic and the geometrical term have been used in all 
cases.In between the refinement cycles the models were subjected to manual rebuilding by 
using XtalView 26. Water molecules have been added by using the standard procedures 
within the ARP/WARP suite 27. The stereochemical quality of the refined models was 
assessed using the program Procheck28. The Ramachandran plot is in all cases of good 
quality.  
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Results and discussion 
Similarly to other PPP family members, PP5 is potently inhibited by the tumor promoters 
okadaic acid, microcystin, cantharidin, calyculin A and tautomycin (Chen et al. 1994, 
Borthwick et al. 2001).   
Here we solved the crystal structure of PP5 in complex with the inhibitors cantharidin, 
cantharidic acid and endothal. The three inhibitors share a common scaffold with three 
condensed ring. Cantharidin has an anhydride moiety while cantharidic acid is directly 
derived from cantharidin after addition of a water molecule, with disruption of the 
anhydride and formation of a dicarboxylic moiety. Endothal differs from the cantharid acid 
only for the presence of two methyls moieties. The three structure of PP5 in complex with 
the inhibitors are of very good quality and the RMSD with PP5-2Mn is 0.15, 0.37 and 0.19 
Å for cantharidin, cantharidic acid and endothal, respectively. Data collection and 
refinement statistics are shown in Tab 1. The two metal ions are coordinated by one 
oxygen for each carbolxylate. 
 
Table 1. Data collection and refinement statistics for PP5 complexed with the inhibitors. 
 
 PP5-cntharidin PP5-cantharidic acid PP5-endothal 
Spacegroup C2 C2 C2 
Cell dimensions (Å, °) a= 153.97 
b= 41.61 
c= 105.90 
β= 96.84 
a= 158.87 
b= 41.77 
c= 104.99 
β= 96.96 
a= 154.54 
b= 41.78 
c= 105.48 
β= 97.28 
Resolution (Å) 40.0 – 2.6 39.4 – 1.7 38.3-2.1 
Unique reflections 20601 (2872) 79891(9610) 39575 (5696) 
Overall completeness (%) 98.7 (96.4) 96.5 (81.1) 99.9 (99.8) 
Rsym (%) 19.2 (38.3) 9.1 (39.0) 11.4 (35.8) 
Multiplicity 3.7 (1.9) 5.5 (3.5) 6.5 (4.9) 
I/(σI) 5.8 (2.3) 14.7 (2.3) 16.3 (3.3) 
Wilson plot B-factor (Å2) 17.3 18.9 21.0 
Rcryst  / Rfree (%) 18.4 / 20.8 19.4 / 23.4 16.2 / 22.7 
Protein atoms per monomer 2528 2528 2528 
Water molecules 846 547 343 
Ions per monomer 2 2 2 
RMSD bond lengths (Å) 0.009 0.020 0.026 
RMSD bond angles (º) 1.58 1.78 1.96 
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The catalytic site of PP5 complexed with endothal and cantharidic acid is shown in Fig.1. 
In the case of cantharidic acid the carboxylic moieties, which are very close to each other in 
the adduct, replace the water molecules which completed metal coordination in the 
dinuclear site. Surprisingly, endothal appears to be rotated of 180° with respect to the 
cantharidic acid, where the oxygen of the furanic ring is only 2.53 Å away from M1.  
On the other hand, cantharidin sits in the catalytic in its open form (i.e. as a cantharidic acid 
molecule), where a double conformation is present. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
While one of the oxygen of each carboxylic acid moiety is still coordinating a metal ion, 
the other oxygen bascules in concert with the other carboxylic moiety in order to maximise 
the distance between the negatively charged groups (Fig. 2). Metal coordination is not 
affected by this conformational equilibrium. 
Arg275 seems to exist in two different conformations which can help in stabilizing the 
inhibitor position in the active site with favorable H-bond interactions with one oxygen of 
one carbolxylate of the ligand. 
 
Fig.1 Crystal structure of  catalytic domain of PP5 complexed with endothal (Green) and cantharidic acid 
(Cyan). 
His244
Asp271
Asn303
M1 M2
His352
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Fig.2. Crystal structure of  catalytic domain of PP5 complexed with cantharidin. 
 
The  mobility of Arg275 seems to be a common feature of the catalytic site of many 
phosphatases. 
Superimposition of crystal structure of related PPPs show that the aminoacid forming the 
active site  are highly conserved. At the same time, the relative mobility of the side chain of 
the Arg275 is manteined. The variation of the position of these residues may have a critical 
role in both the interaction with the substrate and the catalytic mechanism. 
The crystal structure of the adduct of cantharidin with PP5 reveals the capability of Arg275 
to move in order to establish an interaction with an oxygen of the inhibitor. This plasticity 
of the active site makes the design of the inhibitor much more difficult even it can provide 
an additional site of interaction. 
The availability of high resolution strcutures of related compounds complexed with PP5 
made possible a detailed characterization of the catalytic site providing more detailed 
information on structure-activity relationship. 
The distribution of the electronic density revels that the inhibitory capability canthaaridine 
is due to the hydrolysis of the anidridic ring and to the interaction of the free carboxylic 
groups with the metal ions present at the active site. 
In particular the comparison of the binding pose of cantharidin with that of endothal reveals 
a role of the two methyls present only in the former molecule and apparently not involved 
in interactions with PP5. 
Actually, the cantharidic acid is more stronlgy bounded to the catalytic pocket of PP5 than 
endothall thanks to a better coordination of the  metal ions. 
 
Asp271 
Asn303 
M1 
M2 
His244 
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Conclusions 
The complex of the cantharidin and of two structurally related molecules with a 
representative member of PPP family, have been solved for the first time. The analysis of 
the protein ligand complexes reveals the structural determinats of the interaction. In 
particular, has been clarified that the cantharidic acid and not cantharidine is the real 
inhibitor of PP5 since the electronic density is not consistent with the presence of the flat 
anydridic structure of the latter. An other relevant feature revealed by the experimental 
structures is the plasticity of catalytic site that appear to be a common characteristic of all 
the members of the family. In particular, the capability of Arg275 to move inside the 
catalytic site to establish new interactions can provide a further anchoring site to increase 
the affinity and the selectivity of new candidate drugs. 
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NMR-based strategies for ligand screening and drug design 
are widely applied in pharmaceutical research.[1-11] Given the 
versatility of the NMR technique, many different methods 
have been developed to answer questions such as i) does the 
ligand bind, ii) where does it bind, and iii) what is the 
structure of the complex. Some or all of these questions are 
answered using two broad categories of experiments, i.e. the 
so-called ligand-based (Figure 1A) or protein-based (Figure 
1B) experiments.[12-19] 
 
Figure 1. NMR-based strategies for ligand screening are either 
based on the observation of the bulk ligand, L, in exchange 
with the protein-bound ligand (A) or on the observation of the 
protein, P, in the presence of excess ligand (B). A subclass of 
ligand-based experiments is based on the observation of a 
reporter molecule, R, competing with the ligand for the same 
protein binding site (C). 
Ligand-based experiments address question i), while 
protein-based experiments typically address questions ii) and 
iii). Ligand-based experiments require much smaller amounts 
of protein, as their sensitivity depends on the ligand 
concentration (which can be in the high millimolar range) 
rather than on the protein concentration (usually in the low 
micromolar range); therefore, they are  faster and easily 
adaptable to high-throughput screening protocols. A 
particular subclass of ligand-based experiments, called 
competition experiments (Figure 1C), are based on the 
observation of one reporter ligand which may or may not be 
displaced from its binding site by the screened molecules.[20] 
In this case, if the binding site of the ligand is known, also 
question ii) can be answered. The sensitivity of competition 
experiments is similar to that of ligand-based experiments, as 
it is related to the concentration of the reporter ligand and not 
to that of the protein. 
It occurred to us that any ligand-protein binding 
experiment often implies competition with a ubiquitarious 
probe-ligand, i.e water. Indeed, water molecules are almost 
always displaced upon binding of the protein ligand. 
Observation of the water signals instead of  signals of a 
reporter ligand would provide a tremendous increase in 
sensitivity, due to the very high concentration of water 
protons (110 M versus submolar concentration of reporter 
ligand). Unfortunately, this very same feature prevents the 
direct use of water in competition experiments. In fact, the 
very large molar ratio between water and protein and the fact 
that only very few of the many protein-bound water 
molecules are displaced by the ligand make the differential 
effect negligibly small.1 
However there is one case where the NMR parameters of 
a protein-bound water are so strongly altered that the effect is 
easily seen even when it is propagated from the bound to the 
bulk water molecules. This is the case of a water molecule 
coordinated to a paramagnetic metal ion, provided that it 
exchanges with bulk water molecules.2 The presence of 
unpaired electrons, whose magnetic moment is 658 times 
larger than that of the protons, and the close proximity of the 
                                                 
1 Protein-bound water is indeed used in ligand screening, but only as a means to 
transfer magnetization to ligand molecules bound nearby in the so called 
WaterLogsy experiments. 
 
2The maximal effect is observed when the residence time of the metal-bound 
water molecule is shorter or of the same order of the longitudinal relaxation 
time. 
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bound water protons to the paramagnetic center, increase the 
longitudinal (and transverse) relaxation rate of the latter by 
many orders of magnitude.[21] We propose here that water 
bound to a paramagnetic metal in the active site of a 
metalloenzyme which is a pharmaceutically relevant target 
can be an efficient reporter ligand to be used in competition 
experiments, answering questions i) and ii). We show that the 
efficiency of this method compares very favorably with the 
others commonly used. Given the fact that metalloenzymes 
are quite widespread, and that the metal can either be natively 
paramagnetic or be substituted by a paramagnetic one, this 
method can be of fairly general applicability. We have taken 
manganese(II)-activated protein phosphatase 5 (PP5) just to 
give an example. Manganese(II)-activated enzymes alone 
constitute around 15% of all metalloenzymes in the Protein 
Data Bank (PDB),3 and several members of the two most 
studied protein targets in drug-discovery, kinases and 
phosphatases, are manganese-activated.[22-33] Manganese(II) 
is an ideal probe to demonstrate the feasibility of the 
approach, due to its strong paramagnetism and its favorable 
electronic relaxation properties.[21]  
Protein Phosphatase 5 is constituted by two domains, a 
phosphatase domain and a regulatory domain.[34;35] The 
former is responsible for the enzymatic activity. The x-ray 
structures reveal that the phosphatase active site is formed by 
two metal ions placed at the bottom of a shallow pocket. The 
nature and the stoichiometry of the metal ions natively 
present in the catalytic domain of PP5 is still controversial, 
given that Fe2+, Zn2+, and Mn2+ compete for the two metal-
binding sites and are all found present in variable amounts in 
enzyme preparations.[35] The active site structure of PP5 is 
shown in Figure 2. The two metal ions (reported as Mn2+ in 
the original publication) are bridged by a phosphate ion (Pi) 
and by a solvent-donated ligand (W3, presumably a 
hydroxide). One of the two metals is coordinated by a water 
molecule (W2), and other crystallographic molecules are 
present in the active site.[36] 
Figure 2. Active site structure of the catalytic domain of PP5. 
One metal ion is coordinated by Asp271, Asn303, His352, 
His427 and the other by Asp242, His244, Asp271, and a water 
molecule (W2). A phosphate ion (Pi) and a further solvent-
donated ligand (W3), presumably a hydroxide ion, are bridging 
the two metal ions. 
                                                 
3 Unpublished results from our laboratory. 
Four compounds known to be generic phosphatases 
inhibitors, with molecular weight in the 166 to 373 Da range, 
have been selected to test the method. These compounds can 
be considered as typical members of a compound library to be 
used in a high-throughput screening program to identify 
active site-directed PP5 ligands. The binding of the inhibitors 
at the catalytic site is believed to prevent the access of the 
substrate to the catalytic pocket and the subsequent 
interaction with the metal ions.[26] In doing so, the ligands 
may either displace the active site water or block its exchange 
with bulk water molecules: in either case, the propagation of 
relaxation enhancement to the bulk water molecules should 
be abolished. Therefore, PP5 may be a good test case for 
competition experiments with water as the reporter molecule. 
The selected ligands were: i) cantharidin (inset of Figure 
3A and Figure S1), a biologically active natural compound 
known to inhibit several phosphatases at nanomolar 
concentration;[37;38] ii) endothall, a nanomolar inhibitor of 
protein phosphatase 2A (PP2A);[39] iii) exo-3,6-epoxy-
1,2,3,6-tetrahydrophthalic anhydride, a compound structurally 
related to norcantharidin, a micromolar inhibitor of PP2A;[40] 
iv) (-)-p-bromotetramisole, selected due to its ability to mimic 
the action of orthovanadate, a micromolar inhibitor of 
calcineurin (PP2B).[41] The structures of the last three 
compounds are reported in the Supporting Information 
(Figure S1). 
Figure 3. (A) Decrease of the water proton longitudinal 
relaxation rate at 400 MHz and 295 K, in a 370 μM solutions of 
Fe,Mn-PP5 upon addition of cantharidin (inset). (B) Titration 
curves of solutions of Fe,Mn-PP5 (50 µM) with endothall (open 
circles), with (-)-p-bromotetramisole oxalate (squares), and with 
exo-3,6-epoxy-1,2,3,6-tetrahydrophthalic anhydride (triangles) 
at 0.02 MHz and 295 K. 
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Water proton longitudinal relaxation rates (R1) were 
measured at 400 MHz, on 2 µL samples of Fe,Mn-PP5 370 
µM, in the presence of increasing amounts of cantharidin. A 
linear decrease in R1 could be observed until addition of one 
equivalent of cantharidin, after which the effect leveled off 
(Figure 3A). The residual relaxation rate is mostly due to the 
sum of the relaxation rate of pure water (ca. 0.35 s-1) and the 
diamagnetic contribution from other water molecules bound 
to PP5 far from the active site, which can be measured on 
solutions of Fe,Zn-PP5 (not shown). Therefore, the effect of 
cantharidin is consistent with the binding of the ligand to the 
catalytic pocket preventing the access of the solvent to the 
paramagnetic center. 
From Figure 3A it is apparent that the effect is clearly 
detectable, although not strong enough to allow to reduce the 
protein concentration much below the high micromolar range. 
On the other hand, given the strong intensity of the water 
signal, the sample volume can be much smaller than the 2 µL 
volume of the present experiment (see below), so that the 
quantity of enzyme needed is modest (much less than one 
nanomole). 
The concentration of the enzyme could be further 
decreased if the paramagnetic effect were stronger. This is 
predicted to happen at low magnetic field, where the dipole-
dipole coupling between the unpaired electrons and water 
protons is maximal. Indeed, it is well known that solutions of 
paramagnetic metalloproteins exhibit large proton 
longitudinal relaxation rates at values of magnetic field much 
lower than 400 MHz. To explore the field-dependence of the 
longitudinal relaxation rate of water protons in solutions of 
Fe,Mn-PP5, with and without cantharidin, relaxation rate 
profiles at magnetic fields ranging between 0.01 and 40 MHz 
were acquired on 50 µM Fe,Mn-PP5 using a Fast-Field 
Cycling relaxometer.[42] The relaxometric profile of Fe,Mn-
PP5 (Figure 4) is indeed much higher all over the low field 
range with respect to 400 MHz and is typical of a Mn(II) 
profile.[21] The addition of an equimolar concentration of 
cantharidin to a solution of the paramagnetic protein 
decreases the relaxivity down to very low values, i.e. the 
values of Fe,Zn-PP5 (Figure 4). The decrease is much more 
striking than at 400 MHz, despite the enzyme concentration is 
about eight times less. 
The acquired relaxometric profiles clearly indicate that a 
large gain in sensitivity can be achieved by performing the 
relaxation rate measurements at low magnetic field values, 
where the difference in relaxivity between the free and the 
inhibited form of the protein is more than one order of 
magnitude larger than at 400 MHz. 
Such a strong effect also permits a safe estimate of the 
ligand dissociation constants KD, provided they are of the 
order or higher than the concentration of the enzyme. Only an 
upper limit of about 1 µM can be estimated for cantharidin 
with this method, while KD for cantharidin is in the 
nanomolar range.[38] For endothall, similarly to cantharidin, 
the relaxation rate decreases linearly with the concentration, 
while for exo-3,6-epoxy-1,2,3,6-tetrahydrophthalic anhydride 
the dependence on the concentration was non-linear so 
indicating a weaker binding constant (Figure 3B). The fit of 
the experimental relaxation rates, measured at the same 
magnetic field, as a function of the concentration of the latter 
inhibitor provided a KD value of 19 ± 2.5 µM. This value 
compares well with the value of 13 ± 5 µM determined by an 
enzymatic assay (see Supporting Information). Finally, no 
effect was detected upon the addition of the (-)-p-
bromotetramisole (Figure 3B), showing that this molecule 
does not bind PP5 at the metal binding site.  
Figure 4. 1H-NMRD profile of: a 50 µM Fe,Mn-PP5 solution at 
288 K (stars), 295 K (open circles), and 303 K (triangles); a 50 
µM Fe,Zn-PP5 solution at 295 K (diamonds); a 50 µM Fe,Mn-
PP5 solution at 295 K in the presence of an equimolar 
concentration of cantharidin (squares). Dotted lines are only to 
better visualize the field dependence of the water relaxation 
rate. 
Although in the present work the R1 values have been 
acquired in a wide range of magnetic fields using a fast field-
cycling relaxometer, the same information on the protein-
ligand interaction could be achieved by performing the 
measurements at a specific value of the proton Larmor 
frequency. In particular the large difference in relaxivity 
present in the region 15-30 MHz in this case can be exploited 
by using commercial fixed-field relaxometers operating e.g. 
at 20 MHz. These instruments are relatively inexpensive and 
widely used in food analysis, biology and material science, 
and their sensitivity is not much smaller than a field-cycling 
relaxometer. 
The amount of protein needed for the analysis is, together 
with speed, the main determinant of the success of a high-
throughput screening methodology. The abundance of water 
protons makes the application of the present approach 
possible using very small sample volumes. From the present 
results, it can be concluded that at low field one can analyse 
samples with enzyme concentrations as low as 15 µM. With a 
conservative estimate of the minimal solution volume of 15 
µL, the amount of protein needed would be as low as 60 
picomoles, much lower than any other NMR-based method. 
At high field the minimal enzyme concentration would be 
much higher, i.e. around 400 µM, the paramagnetic effect 
being much less pronounced at high field. On the other hand, 
the sensitivity is so high that the sample volume could be in 
principle decreased by orders of magnitude, down to a few 
nanoliters.4 
In a recent review,[14] Meyer et al published a 
comparative table (Table 2) of the merits and drawbacks of 
the most popular NMR-based methods in drug discovery. 
                                                 
4 As an additional bonus, such a small volume ensures that the radiation 
damping phenomenon, that occurs for strong NMR signals and potentially 
makes relaxation measurements inaccurate, cannot be operative 
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Table 1 is based on Table 2 by Meyer et al., with the addition 
of a column for the present water-based method. In summary, 
the water-based strategy can be applied to both large and 
small proteins, does not require labelling, provides the 
binding epitope on the protein5 and does not have lower or 
upper limits for KD (ligand solubility being the upper limit), 
although it does not provide the binding epitope on the ligand 
and does not allow to identify the ligand in a mixture. Above 
all, water-based screening permits the use of unprecedentedly 
small amounts of protein per single assay. 
The data here presented prove that the water-based 
approach can be successfully integrated in a drug discovery 
strategy aimed to design ligands for metalloenzymes where a 
paramagnetic metal ion is already present or can be inserted 
in place of the diamagnetic native metal. The analysis can be 
applied to large libraries of compounds or to a portfolio of 
ligands already identified by different high-throughput 
screening strategies, allowing us to select the molecules 
interacting at the metal binding site and providing, at the 
same time, information on the affinity constant and on the 
binding mode.  
Experimental Section 
The catalytic domain of PP5 corresponding to the construct 
169-499 was expressed in soluble form in E. Coli and prepared 
as either Fe,Zn or Fe,Mn derivative (see Supporting 
Information). The Fe,Mn-enzyme was found to be fully active 
(3.9 ± 0.8 U/µg), while the Fe,Zn derivative was virtually 
inactive (0.1 ± 0.03 U/µg). This finding suggests a physiological 
                                                 
5 A reviewer pointed out that the ligand could bind away from the metal center 
and yet water accessibility be altered by allosteric effects. This is relatively 
uncommon, and in any case detecting such active-site-relevant allosteric effects 
could actually be considered an advantage. 
role for the manganese ion, and further supports the use of the 
Fe,Mn derivative in PP5-directed ligand screening, selection 
and optimisation experiments. 
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Plasmid DNA containing the gene of the human full length PP5 enzyme was kindly provided 
by Prof. D. Barford. The PP5 catalytic domain (PP5c, residues 169-499) was isolated 
fromthe template and then amplified by PCR. GATEWAY technology was used to clone the 
construct into the pENTR/TOPO/TEV vector and a LR reaction was performed to sub-clone 
the gene into the GATEWAY acceptor vector (pDEST30). The PP5c was expressed as His-
GST-binding fusion protein in E. Coli BL21 (DE3) RIPL strain. PP5c was purified by 
Glutathione Sepharose affinity chromatography (Amersham) and then digested with TEV 
protease (Invitrogen). After the digestion 
four vector-derived amino acid residues (Gly-Ser-Phe-Thr) remain at the N-terminus of 
PP5c. Further purification steps were carried out by using a combination of Ni2+-saturated 
HiTrap Chelating column (Amersham) and Superdex 75 26/60 size exclusion 
chromatography (Amersham). The purified protein was checked by ICP mass spectrometry 
and found to contain one 
equivalent of iron and variable amounts of zinc and manganese, accounting for another 
equivalent. Different aliquots were dialyzed against solutions containing either MnCl2 or 
ZnCl2. Apparently, the iron ion was not displaced by dialysis, while the other ion could be 
fully replaced by the selected ion, either zinc(II) or manganese(II). Protein samples were 
concentrated to 50 μM as determined by Bradford assay and activity tested against p-
nitropenyl phosphate (pNPP, Jena Bioscience). For phosphatase activity assays pNPP was 
dissolved in the assay buffer solution (10mM pNPP in 20 mM Tris-HCl pH 7.4, 0.2 μg/mL 
BSA) and stored at 253 K until requested. The reaction was started by the addition of PP5 
(50 nM) to 500 μL of the assay buffer containing 10mM pNPP. Production of pNP was 
followed by monitoring the increased absorbance at 405 nm using a Cary 50 Eclypse 
Spectrophotometer. Activity was expressed as Unit/μg enzyme were one unit is the amount 
of the phosphatase required to release 1 nmol of phosphate from pNPP in one minute at 295 
K under the tested assay conditions. A pNPP molar extinction coefficient of 17.8 μL·nmol-
1·cm-1 was considered. Assay was performed in triplicate and a standard error value was 
obtained. Endothall, exo-3,6-epoxy-1,2,3,6-tetrahydrophthalic anhydride and cantharidin 
were purchased from Sigma. Compounds were dissolved in DMSO at a stock concentration 
of 200 mM and added to solutions of PP5. The compounds were evaluated for their ability to 
inhibit the hydrolysis of pNPP. The enzyme was incubated at 298 K with increasing 
concentration of inhibitor and the absorbance at 405 nm monitored for 3 min after the 
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addition of the substrate. Fitting of rates as a function of inhibitor concentration provided Ki 
values. 
The protein samples (50 μM and 370 μM) in a buffer containing Tris-HCl 50 mM, NaCl 
150mM, DTT 1 mM, at pH 7.5 were analysed by 400 MHz NMR at 295 K and by 
relaxometry at 288, 295, and 303 K. The NMRD profiles were collected with a Stelar fast 
field cycling relaxometer in the 0.01–40 MHz proton Larmor frequency range. The 
instrument provides longitudinal relaxation rate measurements that are affected by an error 
of about ±1%. The analysis of the temperature dependence of the longitudinal water proton 
relaxation rate at low field reveals that, for this paramagnetic protein, τM and T1M are of the 
same order. Actually the Fe,Mn-PP5 relaxivity was not affected by the temperature in the 
range 288-295 K while decreases from 295 to 303 K as shown in 
Figure 4. T1 experiments at high field where recorded with a simple inversion recovery 
scheme at 
295 K on a Bruker AV400 operating at 400.1 MHz and equipped with a BBO probe. 
 
 
 
 
 
Figure S1. Chemical formula of the investigated ligands. 
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In vitro protein synthesis1 
 
 
 
 
 
 
 
 
 
 
 
1Eleonora Talluri done all the Molecular Biology work. 
 
 
 77
Introduction 
Several soluble proteins for NMR analysis have been expressed through the in vitro protein 
expression system, also called cell-free system, using S30 cellular extract from E. coli 
(Tab.1) as well as the same technique has been used for large scale production of integral 
membrane proteins1,2.  
Cell-free protein system technique has been taken into consideration to overcome the 
difficulties experienced in the in vivo expression of interesting  metallophosphatases such as 
PP2A, PP6. The main advantage of this technique consists in the open and flexible nature of 
the cell-free systems. This peculiar feature allows the addition of components to facilitate 
protein folding and introduce modifications, producing proteins in controllable environments 
that may not be accessible in vivo systems. It is also capable of functionally producing both 
disulphide-bonded and membrane proteins, providing a platform for generation of 'difficult-
to-express' proteins. The unique advantages of cell-free protein synthesis has been exploited. 
Expression of PP2A and PP6 have been tested. In addition, the expression of a set of targets 
has been tested to evaluate the capability of the vitro strategy to express proteins that differ 
in molecular weight, origin (human or bacterial protein), toxicity, solubility in water 
enviroment, presence of disulfide bounds. Features of the screening are reported in Tab.2. 
The expression and solubility of the most of the targets was already tested in vivo. 
 
 Tab.1 Soluble Proteins expressed in cell-free  for NMR studies. S30 cellular extract from E.coli has been 
used. 
Name Origin Function NMR 
studi
es 
Other studies Ref. Center/ 
University 
PPiB E.coli isomerase X Selective labeling, DOPA 
incorporation 
3 ANU 
hCypA Human isomerase X Selective labeling, DOPA 
incorporation 
3 ANU 
HMP E.coli flavohaemoglobin X DOPA incorporation 3 ANU 
Dna-
polymeraseΙΙΙ(χ,γ
,ψ subunit) 
E.coli Dna-polymerase X Protein-protein interactions 4 ANU 
Dna-
polymeraseΙΙΙ(τ 
subunit) 
E.coli Dna-polymerase X Combinatorial isotope 
labeling 
5 ANU 
Ras Human oncogene X 13C/15N labeling; 
D-glutamate replacement 
6 RIKEN 
CAT E.coli Cloramphenicol 
acetyltransferase 
X 13C/15N labeling 6 RIKEN 
Transcription 
factors 
A. 
thaliana 
Zinc-binding 
protein 
X Optimization of ligand’s 
concentration 
7 RIKEN 
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Tab.2 Target selection for cell-free high trough-put screening. Proteins having different charatceristics have been chosen and class of protein has been create. For 
some of them, a soluble domain screening, a selective labelling and a coexpression with their partner have been planned. Green Fluorescent Protein and PpiB isomerase 
are not reported in the table even though they were used as positive controll in the expression and solubility screening. 
 
 
Protein name 
 
Origin 
 
Class of protein 
 
Selective  
Labelling 
 planned 
 
Coexpression 
planned 
 
Screening 
Domain  
planned 
  Membrane 
protein 
Protein 
containing
S-S 
Degradation 
In vivo 
Difficult 
to be 
expessed 
in vivo 
Proteases    
Phosphatases (PP6 and PP2A) Human    X    X 
MURR1 Human    X     
Bcl2 Human    X     
CCS Human   X  X     
SCOI Human      X   
Cox11 Human    X     
Cox17 Human  X       
Proteases (MMP12 – MMP1 ) 
 
Human     X    
Calmodulin targets Human   X    X  
YVGZ  Bacterial (E. coli 
B. subtilis) 
        
EDF1-α isophorm Human   X      
Dynactin Human    X     
ATP-Binding domain Human     X     
Menkes  Human X        
Surf  Human X   X     
CusS  Bacterial (E.coli) X   X    X 
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Materials and Methods 
 
The expression of PP2A was tested using the following constructs: 1-290 (PP2Ac), 23-287 
(PP2Ac1). The expression of PP6 was tested using the construct 1-298 (PP6c) and 1-305 
(PP6c1). Gateway tecnology was applied to clone each gene into different plasmid 
expression vectors. Test expression was performed in small scale. The genes cloned through 
Gateway system into pDEST17 were used in cell-free expression. 
The following genes were cloned using Gateway technology: ccs, cuss (full and soluble 
domain), murr1 . 
The following genes were cloned using traditional cloning : Matrix metalloproteases (MMP1 
and MMP12). 
The following genes were already cloned  in our laboratories: edf1-α isophorm (both native 
and TRXA-fused), cox11,cox17, surf, menkes, ATP binding domain, dynactin, scoI ,  
calmodulin target (tuberin, hrpap20, max), yvgz from B. Subtilis and its E. Coli omologue 
and gfp. 
PPiB isomerase from E. Coli and T7RNAP clones were a kindly concession of Prof. Otting. 
PPiB has been used as positive control to test the efficiency of cellular extract in protein 
expression.  
All the DNA plasmid samples were amplified and than purified through MIDI-plasmid 
preparation (Invitrogen)  
All the reagents were prepared and stocked according to Ozawa et al. 4 
The prepration of S30 E.coli extract from E.coli Bl21 (DE3) star and E.coli Bl21 Rosetta 
(DE3) pRARE used the Ozawa’s protocol 5 
 
Results and discussion 
 
Firs step was the production and optimization of the S30 extract concentration (Fig. 1), made 
from both E. coli BL21 (DE3) star and Rosetta pRARE strain. The reaction volume was of 
200 μL. The protein overexpressed was the isomerase PpiB (MW 18KDa). 
The S30 activity was optimized in terms of both S30 and magnesium acetate concentration. 
 S30 E.coli extract from E.coli Bl21 (DE3) star enriched with different chaperone sets was 
also tested to get expression of soluble proteins. 
Cell-free reactions was carried out as described by Ozawa et al.5 except for the dialysis 
system. Membranes from pierce ready to be used were tested (Fig.2) instead of the 
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traditional membrane.  The dilaysis reaction were allowed to proceed in a 24-well microtiter 
plate and expression checked after 1 hour , 3hours, 6 hours and over night. 
 
                                   M     1     2    3     4                                                       1      2      3   4     M 
                                                  
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Small scale dyalisis from PIERCE 
 
Firstly, small scale 50μL test reactions were carried out on PpiB. The new system was as 
productive as the one got with the traditional dialysis system, allowing a scale-down of the 
reaction volume from 200μL to 50μL and reducing the hand-preparation time of the dialysis 
system.  
The expression was verified by SDS-page and then confirmed by western –blotting for all 
the protein containing the His6-tag fused. 
Fig.1  Titration of  S30 extract from  E. coli BL21 (DE3) star (A) and E. coli Rosetta pRARE (B)  
10μL soluble protein+5μ FSB 3X have been mixed and 7μL of sample loaded on 17% acrilamide gel. 
PpiB isomerase has been used as positive control in test expression. 
Optimization of  the 
concentration of S30 extract 
from E. coli Rosetta pRARE 
Optimization of  the 
concentration of S30 
extract from E. coli BL21 
star 
M- Marker 
1-15μL S30 extract 
2-30μL S30 extract 
3-40μL S30 extract 
4-50μL S30 extract 
   PPiB 
18KDa 
18KDa 
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The expression and solubility of the most of the targets (not for all) was already tested in 
vivo. The not tested target were cloned into a pDEST 17 plasmid vector through Gateway 
technology. 
Among these targets, the metalloproteases MMP1 and MMP12 showed the maximum 
expression yield in vivo, even if they were recovered in inclusion bodies. They were cloned 
into the MCSI vector but no expression occurred in vitro. 
Most of the expressed targets were membrane proteins (SCOI, CusS full, SURF). Samples 
were expressed as insoluble according to the fact that the reaction was performed in an 
acqueous environment. The expression of CusS full, but not of the soluble domain, suggests 
that full-length constructs of memrane proteins that are composed of a soluble part 
anchorated to the membrain through two intramembrane fragments, are suitable for cell-free 
expression system. 
The GFP, naturally produced by a jellyfish Aequorea, was easly overexpressed as it was for 
the bacterial YVGZ (both f from B. Subtilis and  E. Coli omologue) and PpiB.  
Among the soluble human targets, the expression was achieved for ATP binding domain, 
even if as insoluble, and EDF1-α isophorm with thioredoxin fusion-tag (Fig.3). The scale-up 
of the reaction for EDF1-α  isophorm sample showed the same yield of the small scale test 
In. n Fig. 3 the scale- up result of EDF1-α  isophorm expression is reported. After a column 
affinity purification and TRXA cutting, a  final yield of less than 1mg/mL of reaction was 
recovered (Fig.4) 
                                                                    1 M       2     3 
                                                                   
 
Fig.3 Cell-free expression of TRXA-EDF1-α in 1mL reaction. Before starting the reaction only a 
background deriving from S30 cellular extract is detectable by SDS- acrilamide gel (1); After 6 hours TRXA-
EDF1-α is expressed. Total fraction (2) and soluble fraction (3) are indicated in the red circle. 
M: Protein marker. 10μL protein+5μ FSB 3X have been mixed and 7μL of sample loaded on 17% acrilamide 
gel.  
 
35KDa 
Protein marker 
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The calmodulin target HRPAP20 His6-fused was overexpressed as insoluble, while native 
protein was not espressed. The difficulty of expression of human-recombinant proteins is a 
real challenge for the in-vitro synthesis, even if one of the main advantages in this system is 
that the protein synthesis conditions can be adjusted and controlled, providing a defined 
environment for the expression and correct folding of individual proteins. For this purpose, 
the addition of detergents into the membrane protein’s reaction may  be useful and it still 
remain to be tested. 
The in vitro attempt to express soluble form of PP2A and PP6 have failed and  the two 
proteins can be recovered only as precipitated samples.  
The addition of structural ions is not widely reported in the literature except for the zinc 7. 
The cell-free reaction in presence of zinc helped the expression of CCS but not the solubility 
even tough this structural ion is naturally bounded to the protein8. 
 
                                             
 
 
MURR1, SD11 and CCS contain rare codons in their gene but E.coli Bl21 Rosetta (DE3) 
pRARE S30 extract was proved to be not more suitable than the E.coli Bl21 (DE3) star S30 
extract for their expression and the same result was obtained. The expression for all the 
reported sample was verified both by SDS-page and western –blotting. 
The expression and solubility of the targets were already tested in vivo except for CCS and 
CusS. All the proteins were overexpressed in incusion bodies except for GFP, PpiB and 
EDF1 α .  
S30 E.coli extract from E.coli Bl21 (DE3) star enriched with different chaperone sets did not 
help the expression of the  proteins in a soluble form. 
TRXA-EDF1-α   After cutting     Protein Marker 
Befor cutting         
Fig.4 TRXA removal by TEV enzyme. TRXA in red circle and  EDF1-α in yellow circle are shown. 
35KDa 
Protein marker 
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A summary of the high through-put screening is reported in Tab.3. 
It was hypothized that the small-scale dialysis system was allowing a faster cell-free 
reaction, thus resulting in  a non-correct folding and insoluble sample. The traditional 
dialysis system was tested for all the expressed proteins with the same result. Different 
Temperature, DTT concentration, RPM were tested without success. 
Further optimization of cell-free reaction conditions must be planned to help the yield of 
protein expression and production of labelled samples to be used both structural and 
biochemical studies. 
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Tab.3 Screening assay : main features and results 
 
Protein 
name 
description Molecular 
weigth 
[Kda] 
Cloning vector Expression 
and solubilty 
in vivo (E. 
coli) 
Expression 
and 
solubility in 
vitro 
CCS  copper 
chaperone for 
SOD1 
30 pDEST17 (His-
tagged) 
not tested insoluble 
MURR1  factor recently 
implicated in 
copper 
homeostasis 
21 pDEST17 (His-
tagged) 
no expression insoluble 
MMP1  Metalloprotease 42 MCSI and pET21 Insoluble No expression 
MMP12 Metalloprotease  42 MCSI and pET21 Insoluble No expression 
Cox11 cytochrome c 
oxidase 
assembly protein 
22 pDEST17(His-
tagged) 
Insoluble No expression 
Cox17  
 
cytochrome c 
oxidase 
assembly protein 
11 pDEST17(His-
tagged) 
Soluble No expression 
CusS Membrane 
protein 
53.7 pDEST17(His-
tagged) 
not tested insoluble 
SURF  membrane 
protein 
28 pDEST17(His-
tagged) 
Insoluble Insoluble 
MENKES  
 
Membrane 
protein 
18 pDEST17(His-
tagged) 
Insoluble N expression 
ATP binding 
domain  
ATP binding 
domain 
40 pDEST17(His-
tagged) 
Insoluble Insoluble 
 
DYNACTIN  
 
Dynain activator 53 pDEST17(His-
tagged) 
Soluble only if 
MBP-tagged 
No expression 
SCOI  
 
protein essential 
for cytochrome c 
oxidase function 
is a Cu(I) -
binding protein 
30 pDEST17(His-
tagged) 
Soluble Insoluble 
 PP6/PP2A 
 
Serine/threonine 
phosphatase 
[PP6 residues 1-
298; 1-305,PP2A 
residues: 1-290; 
23-287 ] 
 
34.3-35 pDEST17(His-
tagged) 
Insoluble Insoluble 
TUBERIN Calmodulin 
target 
26-30 pDEST42(native)-
pDEST17(His-
tagged) 
Insoluble(native) 
Soluble (His-
tagged) 
No expression 
HRPAP20 Calmodulin 
target 
20 pDEST17(Hist 
tagged) 
Insoluble Insoluble 
MAX Calmodulin 
target 
9.8 pDEST42 
(native) 
soluble No expression 
EDF1-α 
isophorm 
(native and 
TRXA-fused) 
 
Calmodulin 
target 
16.3 and 32.3 
 
pET21 
andpET20A 
Insoluble No expression 
(native) 
Soluble TRXA-
fused 
YVGZ from B. 
Subtilis and its 
E. Coli 
omologue 
 
copper-sensing 
repressor that 
regulates the 
copZA operon 
15 pDEST17 (His-
tagged) 
Soluble only with 
MBP-tagged 
Insoluble 
GFP  Green-
fluorescent 
protein 
27  Soluble Soluble 
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Structural biology provides detailed informations on the structure of biological 
macromolecules, with the ultimate goal of investigating the relationship between structure 
and function. The high resolution three-dimensional structure of a protein can be solved in 
the solid state, through X-ray crystallography, or in solution, through NMR spectroscopy.  
With the development of the genome sequencing project, relating functional information to 
each of the proteins encoded in various genomes has become a crucial problem. The 
possibility of inferring from experimental three-dimensional structural data functional 
information more reliable than those derived from sequence comparison methods, has 
prompted worldwide efforts aimed at solving protein structures on a genome-wide scale.  
 
Our research was aimed not only to elucidate the structure of metal-binding proteins and to 
understand the interactions  of the selected enzyme with its targets, but also to develop new 
tools able to  support the structure-based drug design for potential pharmacological targets. 
 
The main steps of a structure-based drug discovery project are : 
1. target selection  
2. Clonign, expression and purification of the target protein 
3. Structural and functional characterization of the target  
4. Development of screening tools 
5. Screening of library of chemicals and identification of lead compounds 
6. Lead optimaization 
 
Human Serine/Threonine Phosphatase PP5 was selected as potential pharmaceutical target 
beacuse is involved in may cellular precesses and the alteration of the catalytic activity may 
lead to many human disease.  Protein sample has been obtained through recombinant 
expression in E. coli system. Investigations on the catalytic domain have been performed to 
refine the biochemical and structural characterization by the use of  ICP-mass, enzymatic 
assay and X-ray spectrospcopy. 
A part of the purified protein was dialyzed against either solutions of Mn(II) or Zn(II)  to 
obtain different metallated protein samples. The manganese-dialyzed-enzyme was found to 
be fully active,  while the zinc derivative was virtually inactive as it was for the not dyalized 
sample. The crystal structure of both metal-loaded protein (Fig.1) and not dyalized PP5 have 
been solved. The first two structures have been showed to be superimposable. A binuclear 
metal-center is present in the  catalytic domain of these proteins.  
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PP5 crystals obtained from the protein dialyzed against Mn2+ revealed the presence of two 
Mn2+ ions in the metal site. On the other hand, X-ray fluorescence and anomalous dispersion 
from PP5 crystals obtained from the protein dialyzed against Zn2+ revealed the presence of 
two Zn2+ ions in the metal site.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the light of these results, the different roles for the two metal ions in the regulation of PP5 
function have to be further investigated. 
 
The paramagnetic properties of the fully active Mn-PP5 (catalytic domain) has been taken 
into account for the development of small ligand screening tools. 
Taking advantage from the presence of a paramagnetic metal in the active site of  the 
pharmaceutically relevant human protein serine threonine phosphatase PP5, water bound to 
the metal can be used as an efficient reporter ligand to perform competition experiments with 
a tremendous increase insensitivity due to the very high concentration of water protons. 
Given the fact that metalloenzymes are quite wide spread, and that the metal can either be 
natively paramagnetic or be substituted by a paramagnetic one, this method should be of 
fairly general applicability. The data presented here show that this water-based approach can 
be successfully integrated into a drug discovery strategy aimed at designing ligands for 
Fig.1 Crystal structure of  Mn-Mn and Zn-Zn-PP5. Residues involved in metal cooridnation  
(Asp242,His244,Asp271;Asp27,Asn303,HEis352,His427) are zoomed  in. 
 
Mn-Mn-PP5 Zn-Zn-PP5 
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metalloenzymes where a paramagnetic metal ion is already present or can be inserted in 
place of the diamagnetic native metal.  
A point we are going  to address is the possible use of the relaxometric approach to 
investigate the binding of activators of PP5. In fact,  PP5 differs from most PPP family 
phosphatases in that the principle substrate targeting, regulatory, and catalytic domains are 
contained in a single polypeptide chain. The displacement of this domain by the binding of 
the TPR domain with activators leads to the activation of PP5 making the paramagnetic site 
accessible to water molecules. Therefore, the activation of PP5 by small ligands can be easly 
monitored observing the increase of proton water relaxation rate. 
 
Results obtained from relaxometric analysis increase the interest in chantaridin and endothal 
as PP5 inhibitors. Due to their low molecular weight, cantharidin and its analogues can be 
considered as leads to investigate the structural features of the binding site of PP5 useful to 
design new candidate drugs. 
The crystal structure of the catalytic domain of PP5  in complex with the inhibitors 
cantharidin, cantharidic acid and endothal has been obtained by socking the lignads on 
crystals of free protein and all the structures solved by X-ray.  
Endothal binds the catalityc pocket rotating in 180°  with respect to the cantharidic acid. 
Moreover, cantharidin sits in the catalytic site as a mixture of open and closed 
conformations, where the closed one seems to be the less populated. Moreover, the Arg275 
mobility gives plasticity to the catalytic site stabilizing the inhibitor position in the active 
site. 
The comparison of the binding pose of cantharidin with that of endothal reveals a role of the 
two methyls present only in the former molecule and apparently not involved in interactions 
with PP5. 
Actually, the cantharidic acid is more stronlgy bounded to the catalytic pocket of PP5 than 
endothall thanks to a better coordination of the  metal ions. The distribution of the electronic 
density revels that the inhibitory capability canthaaridine is due to the hydrolysis of the 
anidridic ring and to the interaction of the free carboxylic groups with the metal ions present 
at the active site. The last aspect must be further elucidated. 
 
The expression  of PP2A and PP6 has been attempted by cell-free approach. Unfortunately, 
both the proteins have been recovered as insoluble samples. Cell-free systems will be further 
optimised in order to improve the expression yield and protein folding. Further development 
of the system  would significantly reduce the cost and enhance the capability for high 
 90
throughput generation of proteins and screening of their function and interactions. It will be 
an  important tool for the future analysis of proteomes. 
